



KIDNEY WEEK

20
23

November 1-5 | Philadelphia, PA

Onsite GUIDE





CORPORATE SUPPORTERS 2023

The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies for their contributions in 2023.

DIAMOND LEVEL



PLATINUM LEVEL



GOLD LEVEL

Mallinckrodt Pharmaceuticals
Novo Nordisk

SILVER LEVEL

Amgen
Ardelyx, Inc.
Baxter Healthcare Corporation
Fresenius Medical Care

Medtronic
Vera Therapeutics
Vertex Pharmaceuticals

BRONZE LEVEL

Apellis Pharmaceuticals
Aurinia Pharmaceuticals
Bayer
bioMérieux
Boehringer Ingelheim Pharmaceuticals, Inc.

Diality
Lilly USA
Natera
Omeros

Table of Contents

Kidney Week Mobile App	2
Welcome	3
Schedule-at-a-Glance	4
Accreditation, CE Credits, MOC Points	6
Certificates of Attendance for International Participants	7
Day-at-a-Glance: Wednesday, November 1 (Early Programs)	9
Exhibitor Spotlights: November 2-4	10
Day-at-a-Glance: Thursday, November 2	12
Day-at-a-Glance: Friday, November 3	30
Day-at-a-Glance: Saturday, November 4	50
Scientific Exposition: November 2-4	67
Day-at-a-Glance: Sunday, November 5	70

Attention US Health Professionals -- To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148) that requires applicable manufacturers and applicable group purchasing organizations to report financial payments made to US physicians and select other US health care professionals, including as part of supported ASN activities. ASN reserves the right to provide information to such entities about US physicians, US physician assistants, and US advanced practice nurses (and their spouses) who participate in selected ASN activities.

Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license.

In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose.

US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below.

To learn more, please go to the US Government's Center for Medicare & Medicaid Services (CMS) website, www.cms.gov/openpayments. Additional information can be found at the American Medical Association's website.

**American Society of Nephrology | www.asn-online.org
1401 H Street, NW | Suite 900 | Washington, DC 20005
Copyright © 2023 ASN**

Download the Kidney Week Mobile App

Navigate the meeting like a pro
with the meeting mobile app.

- Stay organized with current session, exhibitor, and meeting information.
- Receive important real-time communications from ASN.
- Build a personalized schedule and bookmark exhibitors.
- Stay in-the-know and join the social media conversation.
- And more!



GET THE FREE APP SEARCH
FOR "ASN KIDNEY WEEK"



*The Kidney Week Mobile App
is supported by*



Welcome to ASN Kidney Week 2023

ASN proudly welcomes you to Kidney Week, the world's premier nephrology meeting.

At Kidney Week, the world's leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance their careers, learn best practices for treating and improving the lives of people with kidney diseases, and collaborate with colleagues from around the world.

Leading the fight against kidney diseases for over 50 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy and improve the lives of millions of patients.



ASN Council

Michelle A. Josephson, MD, FASN, *President*
Susan E. Quaggin, MD, FASN, *Past President*
Deidra C. Crews, MD, MS, FASN, *President-Elect*
Prabir Roy-Chaudhury, MD, PhD, FASN,
Secretary

Keisha L. Gibson, MD, MPH, FASN, *Treasurer*
Jeffrey S. Berns, MD, FASN, *Councilor*
Linda F. Fried, MD, MPH, FASN, *Councilor*
Crystal A. Gadegbeku, MD, FASN, *Councilor*
Patrick H. Nachman, MD, FASN, *Councilor*

Kidney Week Education Committee

Dianne B. McKay, MD, *Co-Chair*
Mark A. Perazella, MD, MS, FASN, *Co-Chair*
Reza Abdi, MD
Matthew K. Abramowitz, MD, MS, FASN
George L. Bakris, MD, MA, FASN
Nisha Bansal, MD, FASN
Erin F. Barreto, PharmD, MS, FASN
Moumita Barua, MD
Whitney Besse, MD
Hui Cai, MD, FASN
Corey J. Cavanaugh, DO
Jordana B. Cohen, MD, MS, FASN
Mark E. Cooper, MBBS, PhD, FASN
Stanley D. Crittenden, MD, FASN
Donald Fraser, MBChB, PhD
Lorenzo G. Gallon, MD
Rasheed A. Gbadegesin, MBBS, MD, FASN
Orlando M. Gutierrez, MD

Gentzon Hall, MD, PhD
Takashi Hato, MD
Leal C. Herlitz, MD
Jeffrey B. Hodgin, MD, PhD
Tamara Isakova, MD
Beom Seok Kim, MD, PhD
Lisa A. Koester Wiedemann, ANP, CNN-NP
Rachel Lennon, MBBS, PhD
Helen McNeill, PhD
Patrick T. Murray, MD, FASN
Monika A. Niewczas, MD, PhD, MPH
Samir M. Parikh, MD, FASN
Tammy L. Sirich, MD, FASN
Arohan R. Subramanya, MD, FASN
Smitha R. Vidi, MD
David M. White
Anna L. Zisman, MD, FASN

Schedule-at-a-Glance

Thursday, November 2	AM	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session					[Green]							
BCSS, CPS, TS, SS										[Yellow]		
Educational Symposia												
Oral Abstract Sessions												
Poster Sessions								[Blue]	Ask the Author			
Scientific Exposition								[Purple]	Exhibitor Spotlights			
Friday, November 3	AM	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session					[Green]							
BCSS, CPS, TS, SS										[Yellow]		
Educational Symposia		[Orange]										
Oral Abstract Sessions										High-Impact Clinical Trials		
Poster Sessions								[Blue]	Ask the Author			
Scientific Exposition								[Purple]	Exhibitor Spotlights			
Saturday, November 4	AM	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session					[Green]							
BCSS, CPS, TS, SS										[Yellow]		
Educational Symposia												
Oral Abstract Sessions										High-Impact Clinical Trials		
Poster Sessions								[Blue]	Ask the Author			
Scientific Exposition								[Purple]	Exhibitor Spotlights			
Sunday, November 5	AM	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session and ASN Business Meeting					[Green]							
BCSS, CPS, TS, SS									[Yellow]			

LEGEND

BCSS - Basic/Clinical Science Sessions
 CPS - Clinical Practice Sessions

TS - Translational Sessions
 SS - Special Sessions

PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
	Yellow				Yellow	Yellow	Yellow	Yellow		Yellow					
		Orange								Cyan					
	Light Blue	Blue	Blue	Blue	Blue	Blue	Blue	Blue							
	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple					Dark Purple		
														Light Purple	
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
	Yellow				Yellow	Yellow	Yellow	Yellow		Yellow					
		Orange								Cyan					
	Light Blue	Blue	Blue	Blue	Blue	Blue	Blue	Blue							
	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple					Dark Purple		
														Light Purple	
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
	Yellow				Yellow	Yellow	Yellow	Yellow		Yellow					
		Orange								Cyan					
	Light Blue	Blue	Blue	Blue	Blue	Blue	Blue	Blue							
	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple					Dark Purple		
														Light Purple	
PM	12:00	12:30	1:00	1:30	2:00	2:30	3:00	3:30	4:00	4:30	5:00	5:30	6:00	6:30	7:00
	Yellow				Yellow	Yellow	Yellow	Yellow		Yellow					
		Orange								Cyan					
	Light Blue	Blue	Blue	Blue	Blue	Blue	Blue	Blue							
	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple	Light Purple					Dark Purple		
														Light Purple	



EDT to EST Time Change Sunday, November 5
 Don't forget to turn back your clocks one hour.

Accreditation, CE Credits, MOC Points (Annual Meeting, November 2–5)

Learning Objectives

At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to:

1. Identify recent discoveries in basic, translational, and clinical research in nephrology.
2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines.
3. Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.

Target Audience

- Physicians
- PhDs and Other Researchers
- Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Health Care Professionals

Accreditation Statement

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Continuing Medical Education Credits

AMA CREDIT DESIGNATION STATEMENT – PHYSICIANS

The American Society of Nephrology designates this blended learning activity for a maximum of 75.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT DESIGNATION STATEMENT – NURSES

This CE activity is approved for 75.0 ANCC contact hours.

ACPE CREDIT DESIGNATION STATEMENT – PHARMACISTS

This activity has been approved for 75.0 contact hours.

AAPA/NCCPA CREDIT DESIGNATION STATEMENT – PHYSICIAN ASSISTANTS

Physician Assistants may claim a maximum of 75.0 Category 1 credits for completing this activity. NCCPA accepts *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society.

ASN values each participant's review and comments on the quality of ASN's educational activities. Please complete the evaluation, claim credits, and claim MOC at www.asn-online.org/elearning by **December 20, 2023**. Instructions are available on the ASN website and at ASN Services on the Bridge between the Grand Hall and Exhibit Halls in the convention center.

Note: For Early Program credits, please refer to the program materials.

Maintenance of Certification (MOC) Points

The Kidney Week Annual Meeting offers MOC Points for American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) Diplomates with the completion of a reflective statement and commitment-to-change questions in this activity's evaluation. Instructions are available on the ASN website and ASN eLearning Center.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 75 MOC points in the ABIM Maintenance of Certification (MOC) program; and
- 75 MOC points in the ABP Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Statement from ABIM

This course has been developed as an original and independent educational offering based on the public ABIM examination blueprint and is not approved or endorsed by ABIM. In accordance with ABIM policy, no ABIM Board members have been involved in the development of this course. ASN cannot guarantee that attending this course will result in passing the ABIM examination.

Disclosure Statement

It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 12 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside US Food and Drug Administration (FDA)-approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for Kidney Week to complete disclosure forms. Responses are listed on the ASN website, in the meeting platform, and during sessions.

Certificates of Attendance for International Participants


Early Program participants can pick up printed Certificates of Attendance (not CME certificates for US participants) on Wednesday, November 1 at the programs. Annual Meeting participants can access online Certificates of Attendance (not CME certificates for US participants) from November 2, 2023, through February 2, 2024, at <https://show.jspargo.com/asn23/certificateofAttendance/>. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit ASN Services on the Registration Bridge of the convention center.

Visit the ASN Communities Lounge at ASN Kidney Week

Community discussions, networking, and collaboration.

Meet-and-Greet

10:00 a.m. — 11:00 a.m.



Ed Kashi

Photojournalist and Filmmaker

Thursday, Nov. 2

Overview of Communities

Profile components, account preferences, navigation tips

11:00 a.m. — 12:00 p.m.

Mentor Match Program

Enrollment basics, search criteria, building relationships

12:00 p.m. — 1:00 p.m.

Networking and Collaboration

Leveraging connections, sharing stories, team projects

1:00 p.m. — 2:00 p.m.

Friday, Nov. 3

CMMI Listening Session

Join the Center for Medicare and Medicaid Innovation (CMMI) and ASN to discuss the ESRD Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Model.

10:00 a.m. — 11:00 a.m.

Hot Topics

Chronic Kidney Disease, Transplantation, Home Dialysis

11:00 a.m. — 12:00 p.m.

Becoming a Community Leader

Engagement strategies, moderation, replies, and follow-through

12:00 p.m. — 1:00 p.m.

CMMI Listening Session

Join CMMI representatives and ASN staff to ask questions and discuss issues regarding the ETC Model and KCC Model.

1:00 p.m. — 2:00 p.m.

Saturday, Nov. 4

Communities Library

Keyword searching, studies & reports, credible research

10:00 a.m. — 11:00 a.m.

Early Career Focus

STARS, TREKS, in-training exam, the nephrology match

11:00 a.m. — 12:00 p.m.

Themed Communities

Onco-nephrology, Kidney Transplantation, Women's Health & Research

12:00 p.m. — 1:00 p.m.

Open Discussion

New ideas, future directions, lingering questions

1:00 p.m. — 2:00 p.m.

Listen and partake in conversations.



ASN
Communities

DAY-AT-A-GLANCE

Wednesday, November 1

Early Programs

Each Early Program requires separate registration from the Annual Meeting.

Detailed schedules are available at each Early Program room.

7:00 a.m. Onsite Check-In and Continental Breakfast for all 7 Early Programs

Advances in Research Conference: Multi-Omic Analyses of

Tissue Microenvironments in the Kidneys..... Room 108

8:00 a.m. Onsite Sessions

4:45 p.m. Adjourn

Fundamentals of Renal Pathology..... Room 109

8:00 a.m. Onsite Sessions

5:30 p.m. Adjourn

Genetics in Clinical Nephrology..... Room 107

8:00 a.m. Onsite Sessions

5:30 p.m. Adjourn

Glomerular Diseases: 2023 Update..... Ballroom B

Support is provided by an educational grant from Vera Therapeutics.

8:00 a.m. Onsite Sessions

5:40 p.m. Adjourn

Kidney Transplantation: 2023 Update..... Ballroom A

In cooperation with the American Society of Transplantation.

8:00 a.m. Onsite Sessions

5:10 p.m. Adjourn

Maintenance Dialysis: 2023 Update..... Room 204

8:00 a.m. Onsite Sessions

5:00 p.m. Adjourn

Nephrocardiology: An Emerging Field in Medicine..... Room 201

8:00 a.m. Onsite Sessions

6:00 p.m. Adjourn

All Early Programs except the Advances in Research Conference have on-demand presentations that have been available for viewing in the ASN eLearning Center since October 25.

Download the Kidney Week App
For up-to-date meeting information,
search Kidney Week in your app
store or scan the QR code here.



SCAN ME

Theater 1

Exhibitor Spotlight Schedule

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor (no continuing education credit). Seating is limited and available on a first-come, first-served basis.

The 10:00 a.m. presentation includes breakfast. All other presentations include lunch.

Thursday, November 2

10:00 a.m. - 10:45 a.m.

The Dual Dilemma: Navigating Cardiorenal Risk in CKD Associated with T2D

Presented by



12:00 p.m. - 12:45 p.m.

Replacing RASi in IgA Nephropathy: Unique Therapy Targets Two Pathways, with a Patient's Perspective

Presented by



Friday, November 3

10:00 a.m. - 10:45 a.m.

Guideline Considerations for Early Treatment in Lupus Nephritis & Updates on Anemia of CKD

Presented by



12:00 p.m. - 12:45 p.m.

Overcoming the Challenges of Phosphate Management with a High-Potency Approach

Presented by



Saturday, November 4

10:00 a.m. - 10:45 a.m.

Understanding the Complexity of Patients With CKD: Implications for Management

Presented by



12:00 p.m. - 12:45 p.m.

Jardiance® (empagliflozin) tablets: A Peer Review of the Latest Clinical Data and Dosing Recommendations

Presented by



Thursday, November 2

11:00 a.m. - 11:45 a.m.

IgA Nephropathy: Where We Are Now and Where We Are Going

Presented by  **CHINOOK**
THERAPEUTICS
A Novartis Company

1:00 p.m. - 1:45 p.m.

Terlipressin and Albumin Use in Hepatorenal Syndrome

Presented by  **Mallinckrodt**
Pharmaceuticals

Friday, November 3

11:00 a.m. - 11:45 a.m.

A New Paradigm: Rethinking Hyperphosphatemia Management

Presented by  **ardelyx**

1:00 p.m. - 1:45 p.m.

Early Identification and Management in ADPKD Featuring Dialogue With a Patient Ambassador

Presented by  **Otsuka**
Otsuka America Pharmaceutical, Inc.

Saturday, November 4

11:00 a.m. - 11:45 a.m.

A Closer Look at Kidney Preservation in Lupus Nephritis

Presented by  **Aurinia**

1:00 p.m. - 1:45 p.m.

Genetics in Nephrology: What Are We Missing?

Presented by  **natera**

These events are not CE (continuing education) activities.

**KIDNEY
WEEK** 20
23

Theater 2

DAY-AT-A-GLANCE

Thursday, November 2

8:00 a.m. – 9:30 a.m.

Opening Plenary: ASN President's Address, ASN President's Medal, Murphy Award,
State-of-the-Art Lecture..... Hall A

9:30 a.m. – 2:30 p.m.

Morning Break (9:30 a.m. – 10:00 a.m.)..... Exhibit Hall C
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)..... Exhibit Hall C
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)..... Exhibit Hall C

10:00 a.m. – 1:45 p.m.

Exhibitor Spotlights Exhibit Hall C
Please see pages 10-11 for the schedule and topics.

10:30 a.m. – 12:30 p.m.

Basic/Clinical Science Sessions

APOL1 and Kidney Transplantation..... Room 115
Best of ASN Journals: JASN, CJASN, and Kidney360 Ballroom B
Chloride Channels: Physiologic and Pathophysiologic Relevance Room 114 (Nutter Theatre)

Clinical Practice Sessions

Artificial Intelligence and Its Promise to Complement AKI Care..... Room 201
Let's Make It Better: Improving Home Dialysis Therapy Room 113
Present and Future: Hypertension and Cardiovascular Risk Prediction in Children Room 108
Screening for Kidney Diseases: A Call to Action..... Room 120
Social Determinants of BP and CVD in Patients with CKD Room 118
Therapeutic Dilemmas in Glomerular Diseases Room 204

Translational Sessions

Biomarker Studies in Lupus Nephritis: A New Opportunity for Precision Medicine Room 103
Changing Landscape of Diabetic Kidney Disease Treatment,
with the Schrier Endowed Lectureship Ballroom A
Vascular Calcification: Mechanisms, Outcomes, and Emerging Treatment Options..... Room 119

Other Event

Fellows-in-Training Bowl: Elimination Rounds..... Exhibit Hall C

12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 12:30 p.m.

Anemia in CKD and ESKD: From Epidemiology and Pathophysiology to Current Treatments..... Salon I
Real-World Management of Hyperkalemia in Cardiorenal Patients Salon D
What's New with SGLT2 Inhibitors in 2023 Salon A

1:00 p.m. – 2:00 p.m.

Top Trainee Posters..... Exhibit Hall C

2:00 p.m. – 4:00 p.m.

Basic/Clinical Science Sessions

Clinical Trials in Pediatric CKD: Trial with SGLT2 Inhibitors?..... Room 108
Developments in AKI and Repair Mechanisms..... Room 201
Innovative Strategies for Visualization of the Glomerular Basement Membrane:
New Views of an Old Neighborhood Room 103
Integrating Kidney Genetics into Clinical Practice..... Room 107

2:00 p.m. – 4:00 p.m.

Basic/Clinical Science Sessions

New Targets in Diabetic Kidney Disease: Experimental Studies	Room 120
Nutrition, Metabolism, and Cardiovascular Risk in Dialysis	Room 114 (Nutter Theatre)
Organoids with PKD: Defining What They Are and What They Can Do for Us	Room 105
Precision Medicine Approaches for Renal Osteodystrophy	Room 121
Selecting Kidney Donors: Challenges in Evaluating the Appropriate Candidate	Room 115
Transport Mechanisms Along the Renal Tubule: Legacy of Moe Burg	Room 111

Clinical Practice Sessions

Dosing Hemodialysis: One Size Does Not Fit All, with the Eknoyan Endowed Lectureship	Room 113
Updates in Membranous Nephropathy: My Antigen Teacher	Room 204

Translational Sessions

Diabetic Kidney Disease Across the Lifespan: Joint ASN-ADA Session	Ballroom A
My Patient Is Weak and Frail: What Can I Do About It?	Room 109
New Directions in Hypertension Treatment	Ballroom B

Special Sessions

Shovel-Ready Opportunities to Transform Kidney Transplantation in the United States	Room 118
When the Patient Becomes the Teacher: Exploring the Intersections of Disability and Kidney Diseases	Room 119

4:00 p.m. – 4:30 p.m.

Afternoon Break	Foyers of Rooms 201/204, 108, 118
-----------------------	-----------------------------------

4:30 p.m. – 6:00 p.m.

Clinical Practice Sessions

Liver-Kidney Connection: Time to Rethink Hepatorenal Syndrome	Room 201
Recurrent Glomerulonephritis After Kidney Transplantation	Room 114 (Nutter Theatre)
Women's Health and the Kidneys	Room 204

Special Session

Health Care Equity in Education, Clinical Care, and Community Engagement	Room 113
--	----------

Oral Abstract Sessions

AKI Mechanisms: Cellular and Organ Cross-Talk	Room 118
CKD Mechanisms: Prediction, Propagation, and Prevention	Room 119
Glomerular Diseases: Clinical and Translational Studies	Room 103
Hemodialysis Care: Quality, Vascular Access, and Emerging Threats	Room 120
Improving Clinical Outcomes in Diabetic Kidney Disease	Room 121
Investigations in Polycystic and Tubulointerstitial Kidney Diseases	Room 105
Mechanisms and Single-Cell Transcriptional Profiles in Transplant Rejection and Ischemia Reperfusion Injury	Room 115
Mechanisms of Hypertension and Cardiorenal Disease: From the Vasculature to the Gut	Room 108
Onconephrology and Precision Pharmacology	Room 107
Research Advances in Bone and Mineral Metabolism	Room 111

6:00 p.m. – 7:00 p.m.

Welcome Reception	Exhibit Hall C
-------------------------	----------------

Download the Kidney Week App
For up-to-date meeting information,
search Kidney Week in your app
store or scan the QR code here.



Thursday, November 2, 8:00 a.m. – 9:30 a.m.

Opening Plenary..... Hall A

- 8:00 a.m. **ASN President's Address** – Michelle Josephson
8:30 a.m. **ASN President's Medal** – Ed Kashi
8:50 a.m. **Barbara T. Murphy Award** – Rulan Parekh
9:00 a.m. **State-of-the-Art Lecture "Tiny Conspiracies: Cell-to-Cell Communication in Bacteria and New Approaches to Antimicrobials"** – Bonnie Bassler

Thursday, November 2, 10:30 a.m. – 12:30 p.m.

APOL1 and Kidney Transplantation..... Room 115

Moderators: Maria Safar-Boueri, Deirdre Sawinski

- 10:30 a.m. **Patient Perspective on APOL1 in Kidney Transplantation** – Glenda Roberts
11:00 a.m. **APOL1 in Deceased Donor Kidney Transplantation** – Barry Freedman
11:30 a.m. **APOL1 in the Evaluation and Selection of Living Kidney Donors** – Mona Doshi
12:00 p.m. **Recipient APOL1 Genotype Effects in Kidney Transplantation** – Madhav Menon

Best of ASN Journals: JASN, CJASN, and Kidney360.....Ballroom B

ASN thanks JASN, CJASN, and Kidney360 for assistance with this session.

Moderators: Tarek El-Achkar, Morgan Grams

- 10:35 a.m. **My Vision for the ASN Journal Portfolio** – Rajnish Mehrotra
10:45 a.m. **New Insights into Care of the Transplant Patient** – John Gill
11:20 a.m. **Genetic Diseases of the Kidneys** – Michel Chonchol
11:55 a.m. **Advances in CKD and Dialysis** – Jennifer Flythe

Chloride Channels: Physiologic and Pathophysiologic Relevance Room 114 (Nutter Theatre)

Moderators: Hui Cai, Andrew Terker

- 10:30 a.m. **Novel Roles of CIC-Kb Chloride Channel in Collecting Duct Intercalated Cells** – Oleh Pochynyuk
11:00 a.m. **Electrogenic Exchanger CIC5 as a Novel Player in Renal Cysts in Tuberosus Sclerosis** – Grazia Tamma
11:30 a.m. **Impairment in Renal Medulla Development Underlies Salt Wasting in CICK2 Channel Deficiency** – Chih-Jen Cheng
12:00 p.m. **Chloride Transport Modulators as Drug Candidates** – Onur Cil

Artificial Intelligence and Its Promise to Complement AKI Care..... Room 201

ASN thanks the ASN AKINow Artificial Intelligence Workgroup and the Augmented Intelligence and Digital Health Task Force for assistance with this session.

Moderators: Javier Neyra, Danielle Soranno

- 10:30 a.m. **Machine Learning, AI, and Deep Learning: How to Make Sense of the Language Being Used** – Girish Nadkarni
11:00 a.m. **Beyond AKI: How Is AI Improving Care in Critical Illness?** – Azra Bihorac
11:30 a.m. **Not Your Father's Risk Score: Dynamic Risk Assessment and Alerts for AKI** – Jay Koyner
12:00 p.m. **Let the Algorithm Decide the Dose: AI-Guided Dosing in AKI** – Todd Miano

Let's Make It Better: Improving Home Dialysis Therapy..... Room 113

Moderators: Precious McCowan, Rebecca Seshasai

- 10:30 a.m. **A Patient's Perspective: What a Patient Wants to Know About Home Dialysis** – Vanessa Evans
- 11:00 a.m. **Which One: CAPD vs. APD** – Michael Kraus
- 11:30 a.m. **Let's Stay Home: A Look into Keeping Patients at Home** – Christopher Chan
- 12:00 p.m. **Seamless Transition: Transitioning the Pediatric Patient to Home Hemodialysis** – Sarah Swartz

Present and Future: Hypertension and Cardiovascular Risk Prediction in Children Room 108

Moderators: Kevin Meyers, Christine Sethna

- 10:30 a.m. **Novel Risk Factors for Neonatal Hypertension and Future Directions** – Janis Dionne
- 11:00 a.m. **Predictors of Target Organ Damage in Youth: SHIP-AHOY** – Elaine Urbina
- 11:30 a.m. **Novel Biomarkers for Cardiovascular Risk Assessment in Pediatrics** – Manish Sinha
- 12:00 p.m. **Machine Learning for Developing Prediction Models in Pediatric Hypertension and Kidney Diseases** – Sunjae Bae

Screening for Kidney Diseases: A Call to Action..... Room 120

Moderators: Susan Quaggin, Matthew Weir

- 10:30 a.m. **Practical Models to Collaborate with Primary Care to Screen for Kidney Diseases** – Lesley Inker
- 11:00 a.m. **Economical and Health Consequences of Current Screening Patterns for Kidney Diseases** – Marika Cusick
- 11:30 a.m. **Missed Opportunity? Screening for Kidney Diseases in Children and Young Adults** – Joseph Flynn
- 12:00 p.m. **Screening for Kidney Diseases: A Patient's Perspective** – Morgan Reid

Social Determinants of BP and CVD in Patients with CKD..... Room 118

Moderators: Dinushika Mohottige, Julia Scialla

- 10:30 a.m. **Structural Racism and the Neighborhood Environment in Patients with CKD and Hypertension** – Anika Hines
- 11:00 a.m. **Social Determinants of BP Among Hispanic Communities** – Tali Elfassy
- 11:30 a.m. **Race, Biomarkers, and CVD in Patients with CKD** – Susanne Nicholas
- 12:00 p.m. **Barriers to Adequate Care and Resulting Inequities in Hypertension Control** – Joseph Lunyera

Therapeutic Dilemmas in Glomerular Diseases Room 204

Support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Tingting Li, Shikha Wadhvani

- 10:30 a.m. **Appropriate Use of Glucocorticoids in IgA Nephropathy** – Richard Lafayette
- 11:00 a.m. **Can Rituximab Replace the Modified Ponticelli Regimen in Membranous Nephropathy?** – Laurence Beck
- 11:30 a.m. **When Glucocorticoids Are Not Enough: Approach to Steroid-Resistant FSGS** – Laura Mariani
- 12:00 p.m. **SGLT2 Inhibitors in Primary Glomerulopathies: Is It Time?** – Paola Romagnani

Biomarker Studies in Lupus Nephritis: A New Opportunity for Precision Medicine Room 103

Moderators: Jeffrey Hodgkin, Cynthia Nast

- 10:30 a.m. **Overview and Clinical Utility of Biomarkers in Lupus Nephritis** – Dawn Caster
- 11:00 a.m. **Application of Single-Cell RNA Sequencing in Molecular Profiling of Lupus Nephritis** – Arnon Arazi
- 11:30 a.m. **Renal Pathologic Correlates of Biomarker and Molecular Studies** – Ingeborg Bajema
- 12:00 p.m. **Current Biologic-Targeted Therapies in Lupus Nephritis** – George Bertias

Changing Landscape of Diabetic Kidney Disease Treatment, Including the Robert W. Schrier, MD, Endowed Lectureship..... Ballroom A

ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Schrier Endowed Lectureship.

Moderators: Sylvia Rosas, Katherine Tuttle

- 10:30 a.m. **Novel Therapies: On the Mechanisms of Action: The Robert W. Schrier, MD, Endowed Lectureship** – Thomas Coffman
- 11:00 a.m. **Unmet Treatment Needs for Diabetic Kidney Disease** – Linda Fried
- 11:30 a.m. **Are SGLT2 Inhibitors New Again?** – William Herrington
- 12:00 p.m. **GLP1 Receptor Agonists: On the Mechanism** – Daniel Drucker

Vascular Calcification: Mechanisms, Outcomes, and Emerging Treatment Options Room 119

Moderators: Wei Chen, Jason Stubbs

- 10:30 a.m. **New Insights into the Pathophysiology of Vascular Calcification** – Abolfazl Zarjou
- 11:00 a.m. **Burden of Vascular Calcification in CKD: Epidemiology and Outcomes** – Tara Chang
- 11:30 a.m. **Evolution of Calcemic Uremic Arteriopathy: Risk Factors and Treatments** – Sagar Nigwekar
- 12:00 p.m. **Landscape of Potential Therapeutics for Vascular Calcification: From Old to New** – Marc Vervloet

Fellows-in-Training Bowl: Elimination Rounds.....Futures Theater - Exhibit Hall C

Support is provided by Calliditas Therapeutics.

Note: Continuing education credits are not being offered for this activity.

Thursday, November 2, 12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 12:30 p.m. Lunch is provided.

Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Anemia in CKD and ESKD: From Epidemiology and Pathophysiology to Current Treatments.....Salon I

Support is provided by an educational grant from GSK.

- 12:45 p.m. **Introduction: Overview of the Epidemiology of Anemia in CKD** – Neeraj Sharma (Moderator)
- 12:55 p.m. **Mechanisms of Anemia in Kidney Diseases** – Kirsten Johansen
- 1:15 p.m. **Optimal Anemia Management in CKD and ESKD** – Daniel Coyne
- 1:35 p.m. **Questions and Answers**

Real-World Management of Hyperkalemia in Cardiorenal Patients Salon D

Support is provided by an educational grant from CSL Vifor.

- 12:45 p.m. **Introduction** – Joshua Rein (Moderator)
- 12:55 p.m. **Advances in the Regulation of Potassium Homeostasis by RAAS and Other Hormonal Factors** – Paul Welling
- 1:15 p.m. **Updated Management of Chronic Hyperkalemia in Cardiorenal Patients: A Practical Approach** – Csaba Kovcsdy
- 1:35 p.m. **Questions and Answers**

What's New with SGLT2 Inhibitors in 2023.....Salon A

Support is provided by an educational grant from AstraZeneca.

- 12:45 p.m. **Introduction** – Steven Coca (Moderator)
- 12:55 p.m. **Moving Toward Goal-Directed Medical Therapy in CKD: Updates in SGLT2 Inhibitors and Use with Other Novel Therapies** – Ian de Boer
- 1:15 p.m. **Pearls and Pitfalls of Implementing SGLT2 Inhibitors to the Bedside** – Aisha Shaikh
- 1:35 p.m. **Questions and Answers**

Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Clinical Trials in Pediatric CKD: Trial with SGLT2 Inhibitors?..... Room 108

ASN thanks the Kidney Health Initiative for assistance with this session.

Moderators: Susan Furth, William Herrington

- 2:00 p.m. **Designing Trials in Pediatric CKD: Hurdles and Solutions** – William Smoyer
- 2:30 p.m. **Journey Through CKD: A Family's Perspective** – Austin Lee, Clarissa Lee
- 3:00 p.m. **SGLT2 Inhibitors and Kidneys: What We Know So Far** – Marva Moxey-Mims
- 3:30 p.m. **Conceptual Model for Pediatric Trials: SGLT2 Inhibitors in Children with CKD** – Zubin Modi

Developments in AKI and Repair Mechanisms..... Room 201

Moderators: Subhashini Bolisetty, Lloyd Cantley

- 2:00 p.m. **Healthy and Injured Cell States in the Human Kidney** – Matthias Kretzler
- 2:30 p.m. **Cell Death to Efferocytosis: Clearing the Way for Recovery** – Sho Morioka
- 3:00 p.m. **Long-Term Cell Fate After AKI: Tracing the Way Forward** – Louisa Gerhardt
- 3:30 p.m. **Maladaptive Repair, Dedifferentiation, and Cell Senescence** – Craig Brooks

Innovative Strategies for Visualization of the Glomerular Basement Membrane:

New Views of an Old Neighborhood Room 103

Support is provided by an educational grant from Traver Therapeutics, Inc.

Moderators: Jennie Lin, Lori O'Brien

- 2:00 p.m. **Watching Their Steps: Visualizing Podocyte Processes on Micropatterned Substrates** – Hani Suleiman
- 2:30 p.m. **Using Intravital Imaging to Probe the Mechanisms of Collagenopathy** – Janos Peti-Peterdi
- 3:00 p.m. **Don't Forget to Stretch: New Views of the Filtration Barrier with Expansion Microscopy** – Lorenz Sellin
- 3:30 p.m. **Up Close and Personal: Quantifying Slit Diaphragm Injury at Super Resolution** – Nicole Endlich

Integrating Kidney Genetics into Clinical Practice Room 107

Moderators: Mathieu Lemaire, Jordan Nestor

- 2:00 p.m. **Interpreting Genetic Testing and Variants of Unknown Significance** – Anthony Bleyer
- 2:30 p.m. **Making the Economic Argument for Genetic Testing to Policy Makers** – Catherine Quinlan
- 3:00 p.m. **Overview of Reverse Phenotyping in Genetic Kidney Diseases** – Alexander Chang
- 3:30 p.m. **Incorporating Genetic Testing into Clinical Practice: A Real Life Experience** – Neera Dahl

New Targets in Diabetic Kidney Disease: Experimental Studies Room 120

Moderators: Farhad Danesh, Shuta Ishibe

- 2:00 p.m. **NETosis** – Berend Isermann
- 2:30 p.m. **NADPH Oxidase** – Assaad Antoine Eid
- 3:00 p.m. **Inflammasome** – Karin Jandeleit-Dahm
- 3:30 p.m. **Advanced Glycation End Products (AGEs) and Their Precursors (Methylglyoxal [MGO])** – Nordin Hanssen

Nutrition, Metabolism, and Cardiovascular Risk in Dialysis Room 114 (Nutter Theatre)

ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Shweta Bansal, Marcello Tonelli

- 2:00 p.m. **Lipids, Metabolism, and Cardiovascular Risk in Patients on Dialysis** – Christoph Wanner
- 2:30 p.m. **Peritoneal Glucose Handling and Therapeutic Strategies to Reduce Absorption** – Carl Öberg
- 3:00 p.m. **Salt, Inflammation, and Cardiac Injury in Patients on Dialysis** – Christopher McIntyre
- 3:30 p.m. **Let's Get Moving! The Role of Exercise in Cardiovascular Health of Patients on Dialysis** – Kirsten Johansen

Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Organoids with PKD: Defining What They Are and What They Can Do for Us Room 105

Moderators: Jennifer Harder, Peter Igarashi

- 2:00 p.m. **Advances, Limitations, and New Hypotheses from Organoid Modeling of Ciliopathy and ADPKD Genes** – Benjamin Freedman
- 2:30 p.m. **Organoid-on-a-Chip Model of Human ARPKD Reveals Mechanosensing** – Ryuji Morizane
- 3:00 p.m. **Organoid Model of ADPKD for Mechanism and Drug Screening** – Cheng “Jack” Song
- 3:30 p.m. **Adult Human Kidney Organoids Originate from CD24+ Cells and Can Model ADPKD** – Rafael Kramann

Precision Medicine Approaches for Renal Osteodystrophy Room 121

Moderators: Charles Ginsberg, Sharon Moe

- 2:00 p.m. **Renal Osteodystrophy as a Heterogeneous Syndrome** – Marciana Laster
- 2:30 p.m. **Use of Bone Turnover Markers for Clinical Management of Renal Osteodystrophy** – Hanne Joergensen
- 3:00 p.m. **Novel Circulating and Noncirculating Biomarkers as Tools to Identify Renal Osteodystrophy Subgroups** – Thomas Nickolas
- 3:30 p.m. **New Approaches to Better Understand Heterogeneous Pathophysiology of Renal Osteodystrophy Subtypes** – Valentin David

Selecting Kidney Donors: Challenges in Evaluating the Appropriate Candidate Room 115

Moderators: Sookhyeon Park, Leonardo Riella

- 2:00 p.m. **Living Kidney Donors with Obesity and Metabolic Syndrome: OK to Donate vs. When to Lose Weight** – Sunita Singh
- 2:30 p.m. **Prospective Kidney Donor with a Family History of Kidney Disease: When to Use Genetic Testing** – Nicolae Leca
- 3:00 p.m. **Living Kidney Donation Does Not End with the Transplant: Implementation of Long-Term Follow-Up** – Aneesha Shetty
- 3:30 p.m. **Pre- and Postdonation GFR** – Emilio Poggio

Transport Mechanisms Along the Renal Tubule: Legacy of Moe Burg Room 111

Moderators: Robert Hoover, Jeff Sands

- 2:00 p.m. **Moe Burg and His Contributions to Science** – Mark Knepper
- 2:30 p.m. **Viewing Cortical Collecting Duct Function Through Phenotype-Guided Single-Tubule Proteomics** – Nina Himmerkus
- 3:00 p.m. **New Insights into Regulatory Pathways Mediating Salt Reabsorption Regulation by Arginine Vasopressin** – Maria Castañeda-Bueno
- 3:30 p.m. **Moe Burg, the Molecular Crowding Hypothesis, and WNK Kinases** – Arohan Subramanya

Dosing Hemodialysis: One Size Does Not Fit All, Including the Garabed Eknoyan, MD, Endowed Lectureship..... Room 113

ASN gratefully acknowledges Wadi N. Suki, MD, for support of the Eknoyan Endowed Lectureship. ASN thanks the ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.

Moderators: Timothy Meyer, Susan Wong

- 2:00 p.m. **Thrice Weekly Hemodialysis and Kt/V_{urea}: Carved in Stone? The Garabed Eknoyan, MD, Endowed Lectureship** – Laura Dember
- 2:30 p.m. **Value of Residual Kidney Function: What Hemodialysis Cannot Replicate** – Tariq Shafi
- 3:00 p.m. **Incremental Hemodialysis in Patients with Residual Kidney Function: Is It Possible?** – Mariana Murea
- 3:30 p.m. **Economic Considerations of Individualizing Hemodialysis** – Kevin Erickson

Updates in Membranous Nephropathy: My Antigen Teacher..... Room 204

Support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Shane Bobart, Silke Brix

- 2:00 p.m. **Antigens in Membranous Nephropathy: A Discussion of the Clinicopathologic Features and Nomenclature** – Sanjeev Sethi
- 2:30 p.m. **Mechanisms of Injury in Glomerular Diseases** – Nicola Tomas
- 3:00 p.m. **Updates on NELL-1-Associated Membranous Nephropathy: More Discoveries and More Questions** – Tiffany Caza
- 3:30 p.m. **When to Skip the Biopsy in Membranous Nephropathy** – Paolo Cravedi

Shovel-Ready Opportunities to Transform Kidney Transplantation in the United States..... Room 118

Moderators: Scott Bieber, Roslyn Mannon

- 2:00 p.m. **Modernizing the US Transplant Network** – Suma Nair
- 2:30 p.m. **Advancing Accountability to Better Serve Patients** – Jean Moody-Williams
- 3:00 p.m. **The Centers for Medicare and Medicaid Innovation's Role in Improving Kidney Transplant Care** – Tom Duvall
- 3:30 p.m. **Catching Up with Modern Technology: Opportunities to Better Serve Patients in the 21st Century** – Molly McCarthy

When the Patient Becomes the Teacher: Exploring the Intersections of Disability and Kidney Diseases..... Room 119

Moderators: Amrita Mahesh, Curtis Warfield

- 2:00 p.m. **Disability 101: The ADA, Disability Identity, and Beyond** – Ken Sutha
- 2:30 p.m. **Functionality and Quality of Life: Experiences of People with Physical Disabilities** – Cynthia Delgado
- 3:00 p.m. **Leveraging Provider Personal Experience with Mental Illness in the Care of People with Kidney Diseases** – Justin Bullock
- 3:30 p.m. **Learning Through Lived Experience: Panel Discussion** – Alex Goodman

Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Diabetic Kidney Disease Across the Lifespan: Joint ASN-ADA Session Ballroom A *In cooperation with the American Diabetes Association.*

Moderators: Amy Mottl, Susanne Nicholas

- 2:00 p.m. **Diabetes Management in Youth with Type 2 Diabetes** – Steven Kahn
- 2:30 p.m. **Diabetic Kidney Disease in Youth with Type 2 Diabetes: The Magnitude of the Problem** – Petter Bjornstad
- 3:00 p.m. **Apoptosis in Diabetic Kidney Disease** – Andrzej Krolewski
- 3:30 p.m. **Targeting Senescence in Diabetic Kidney Disease** – LaTonya Hickson

My Patient Is Weak and Frail: What Can I Do About It?..... Room 109 *ASN thanks KDIGO for assistance with this session.*

Moderators: Matthew Abramowitz, Elizabeth Lorenz

- 2:00 p.m. **Frailty and Physical Dysfunction in Patients with CKD: Mechanisms, Assessments, and Outcomes** – Andrew Nixon
- 2:30 p.m. **Impact of Frailty on Kidney Transplantation Outcomes** – Mara McAdams-DeMarco
- 3:00 p.m. **Therapeutic Implications of Frailty: ESKD Planning, KDIGO Guidelines, Exercise, and Beyond** – Elke Schaeffner
- 3:30 p.m. **How to Talk to Patients About Frailty** – Rasheeda Hall

New Directions in Hypertension TreatmentBallroom B

Moderators: George Bakris, Karen Griffin

- 2:00 p.m. **Primary Hyperaldosteronism: An Unappreciated Cause of CKD** – Gordon Williams
- 2:30 p.m. **Atrial Natriuretic Peptide: An Alternative BP-Lowering Agent** – John Burnett
- 3:00 p.m. **Angiotensinogen Knockouts and Resistant Hypertension** – Akshay Desai
- 3:30 p.m. **Aldosterone Synthetase Inhibitors as Alternatives to Spironolactone** – Nancy Brown

Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Liver-Kidney Connection: Time to Rethink Hepatorenal Syndrome Room 201

Moderators: Andrew Allegretti, Justin Belcher

- 4:30 p.m. **Reliably Assessing Kidney Function in Cirrhosis: How Close Is the Light at the End of the Tunnel?** – Mitra Nadim
- 4:50 p.m. **“HepatoCardioRenal” Syndrome: Heart as the Neglected Player in HRS** – Amir Kazory
- 5:10 p.m. **When a Physical Exam Needs a Boost: The Role of POCUS in Volume Management of HRS** – Abhilash Koratala
- 5:30 p.m. **Benefits and Risks of Terlipressin Therapy in HRS** – Florence Wong

Recurrent Glomerulonephritis After Kidney Transplantation Room 114 (Nutter Theatre)

Moderators: Zahraa Hajjiri, Astrid Weins

- 4:30 p.m. **Recurrent Membranous Nephropathy** – Fernando Fervenza
- 4:50 p.m. **Thrombotic Microangiopathies After Kidney Transplantation: Diagnosis, Prevention, and Therapy** – Anthony Chang
- 5:10 p.m. **Recurrent Primary FSGS: Can Human Kidney Organoids Be Used to Monitor Disease Activity?** – Lorenzo Gallon
- 5:30 p.m. **Recurrent IgA Nephropathy, C3 Glomerulopathy, and Membranoproliferative Glomerulonephritis** – Carla Nester

Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Women's Health and the Kidneys Room 204

In cooperation with Women in Nephrology (WIN).

Moderators: Jessica Kendrick, Andrea Oliverio

- 4:30 p.m. **Updates on Pathophysiology, Management, and Outcomes of Pre-Eclampsia** – S. Ananth Karumanchi
- 4:50 p.m. **Hypertension in Pregnancy: Management and Long-Term Outcomes** – Vesna Garovic
- 5:10 p.m. **Epidemiology and Outcomes of Pregnancy in Patients on Dialysis** – Silvi Shah
- 5:30 p.m. **Abortion Laws and Kidney Diseases** – Julie Ingelfinger


Health Care Equity in Education, Clinical Care, and Community Engagement..... Room 113

ASN thanks the ASN Health Care Justice Committee for assistance with this session.

Moderators: Keith Norris, Valerie Nwanji

- 4:30 p.m. **Addressing Systemic Racism in Training Program Education** – Tanjala Purnell
- 5:00 p.m. **Serving the Population in Need: Why Diversity in Clinical Trials Matters** – Flor Alvarado
- 5:30 p.m. **Patient Advisory Boards: Engaging the Patients and Their Community to Shape Equity in Innovations** – Vanessa Evans

Join the ScanHunt Game in the Meeting App



Scan various QR codes in the convention center and the Philadelphia Marriott Downtown to earn points. Participants with 100 or more points will be entered to win one of 3 complimentary registrations for Kidney Week 2024 in San Diego, CA.

Oral Abstract Sessions

AKI Mechanisms: Cellular and Organ Cross-Talk Room 118

Moderators: Mark de Caestecker, Michelle Starr

- 4:30 p.m. **TH-OR01 Heart-Specific LIM Protein (CSRFP3) as a Novel Cardiorenal Connector in Acute Cardiorenal Syndrome-Related CKD Progression** – Yoshio Funahashi
- 4:39 p.m. **TH-OR02 The Epidermal Growth Factor Receptor Is an Essential Mediator of Interstitial Fibrosis Development Following AKI** – Shirong Cao
- 4:48 p.m. **TH-OR03 Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na⁺/K⁺ ATPase Activity** – Nadezhda Zheleznova
- 4:57 p.m. **TH-OR04 Analysis of the Immune Cell Landscape Identifies Immunosenescence as a Therapeutic Target in Rhabdomyolysis-Induced AKI** – Snigdha Rao
- 5:06 p.m. **TH-OR05 Novel Anti-Inflammatory Effects of IL-1 Receptor in Kidney Myeloid Cells Following AKI** – Yanting Chen
- 5:15 p.m. **TH-OR06 The Kidney-Gut-Brain Axis in AKI** – Jihyun Yang
- 5:24 p.m. **TH-OR07 Spatial Multi-Omic Atlas of Pyelonephritis** – Xin Wang
- 5:33 p.m. **TH-OR08 Differential Roles of Regnase3 in Resident Macrophages vs. Renal Tubular Epithelial Cells in Kidney Injury** – Chenyu Li
- 5:42 p.m. **TH-OR09 Role of YB-1 in the Early Pathogenesis of Acute Respiratory Distress Syndrome (ARDS) and Associated Renal Damage** – Anna Leitz
- 5:51 p.m. **TH-OR10 Injured Tubular Epithelia-Derived CCN1 Promotes the Mobilization of Fibroblasts Toward the Injury Sites at the Acute Phase After Kidney Injury** – Tomohiro Nakata

CKD Mechanisms: Prediction, Propagation, and Prevention Room 119

Moderators: Mary Choi, Leslie Gewin

- 4:30 p.m. **TH-OR11 Unified Cross-Species Kidney Single-Cell Atlas: Unraveling Conserved Cellular Features and Species-Specific Adaptations** – Konstantin Kloetzer
- 4:39 p.m. **TH-OR12 Extracellular miRNAs as Predictors of CKD Progression** – Anvesha Srivastava
- 4:48 p.m. **TH-OR13 Alternative Splicing in CKD** – Samer Mohandes
- 4:57 p.m. **TH-OR14 Adenine Accumulation Induced by Hypoxia in Kidney Organoids** – Akihiro Minakawa
- 5:06 p.m. **TH-OR15 Induced Senescent Cells Recruit Leukocytes and Permit Their Own Clearance from Healthy Young Kidneys** – Marie Docherty
- 5:15 p.m. **TH-OR16 Identification of Noninvasive Biomarkers Reflecting Cellular Mechanisms of Endothelin A (ETA) Receptor Activity and Atrasentan Response in CKD** – N. Eric Olson
- 5:24 p.m. **TH-OR17 LACTB Is a Kidney C Mitochondrial Metabolism** – Shen Li
- 5:33 p.m. **TH-OR18 Glutathione-Specific γ -Glutamylcyclotransferase 1 (CHAC1) Is a Kidney Disease Risk Gene by Controlling Ferroptosis** – Kolligundla Prasanna
- 5:42 p.m. **TH-OR19 Calprotectin Is Associated with Vascular Calcification and Cardiovascular Complications During CKD** – Julie Klein
- 5:51 p.m. **TH-OR20 PCSK9 Targets Megalin in the Kidney Proximal Tubule and Aggravates Proteinuria in Nephrotic Syndrome** – Sandra Hummelgaard

Glomerular Diseases: Clinical and Translational Studies.....Room 103

Moderators: Salem Almaani, Michelle O'Shaughnessy

- 4:30 p.m. [TH-OR21](#) **Prediction of Kidney Failure Using Multiple Data Domains in Glomerulonephropathy: A CureGN Study** – Laura Mariani
- 4:39 p.m. [TH-OR22](#) **Plasma Metabolic Profiles and Clinical Outcomes in Focal Segmental Sclerosis (FSGS) and Minimal Change Disease (MCD)** – Takaya Ozeki
- 4:48 p.m. [TH-OR23](#) **Idiopathic Collapsing Glomerulopathy Is Associated with APOL1 High-Risk Genotypes or Mendelian Variants in Most Affected Individuals in a Highly Admixed Population** – Precil Neves
- 4:57 p.m. [TH-OR24](#) **Anti-Nephrin Antibody as a Potential Etiology in Primary Focal Segmental Sclerosis (FSGS)** – Claire Avillach
- 5:06 p.m. [TH-OR25](#) **Exploring Epitope Spreading of PLA2R and Its Clinical Relevance in Idiopathic Membranous Nephropathy (IMN) Based on Yeast Surface Display System** – Yanan Liu
- 5:15 p.m. [TH-OR26](#) **eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NeflgArd Phase 3 Trial** – Richard Lafayette
- 5:24 p.m. [TH-OR27](#) **Safety and Efficacy of Felzartamab in Primary Membranous Nephropathy (PMN): Final Analysis of the M-PLACE Study** – Brad Rovin
- 5:33 p.m. [TH-OR28](#) **Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the ADVOCATE Trial** – Duvuru Geetha
- 5:42 p.m. [TH-OR29](#) **Repeat Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis** – Samir Parikh
- 5:51 p.m. [TH-OR30](#) **Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trial** – Brad Rovin

Hemodialysis Care: Quality, Vascular Access, and Emerging Threats.....Room 120

Moderators: Michael Allon, Matthew Rivara

- 4:30 p.m. [TH-OR41](#) **The Relationship Between Patient Activation and Clinical Outcomes: A Longitudinal, Retrospective, Observational Study** – Wael Hussein
- 4:39 p.m. [TH-OR42](#) **Self-Efficacy and Social Support Determine Self-Reported Health in Hemodialysis Patients** – Krister Cromm
- 4:48 p.m. [TH-OR43](#) **Impact of Conservative Management vs. Dialysis on the Survival of US Veterans with Advanced CKD** – Connie Rhee
- 4:57 p.m. [TH-OR44](#) **Encouraging a Standardized ESKD Transition Approach in a Comprehensive Kidney Care Contracting (CKCC) Program Is Associated with Increased Optimal Dialysis Starts** – Roy Marcus
- 5:06 p.m. [TH-OR45](#) **Higher Patient-to-Patient Care Technician Ratios Associated with Worse Outcomes Among US In-Center Hemodialysis Patients** – Laura Plantinga
- 5:15 p.m. [TH-OR46](#) **The Impact of Affordable Care Act Medicaid Expansions on Dialysis Facility Medicaid Enrollment and Quality Measures** – Allison Reaves
- 5:24 p.m. [TH-OR47](#) **Roles of Matrix Metalloproteinase-2 and ETS Proto-Oncogene 1 in Rodent Arteriovenous Fistula Development** – Hannah Northrup
- 5:33 p.m. [TH-OR48](#) **Long-Term Intervention Rate with Drug-Coated Balloons for Dysfunctional Arteriovenous (AV) Fistulas: Meeting KDOQI Targets in the IN.PACT AV Access Trial** – Anjana Gopal
- 5:42 p.m. [TH-OR49](#) **Extreme Heat Exposure and Mortality Among Patients Receiving Dialysis** – Matthew Blum
- 5:51 p.m. [TH-OR50](#) **Exposure to Wildfire-Related Particulate Matter and Risk of Hospitalization and Mortality Among Hemodialysis Patients** – Hyeonjin Song

Improving Clinical Outcomes in Diabetic Kidney Disease.....Room 121

Moderators: David Cherney, Ricardo Correa-Rotter

- 4:30 p.m. [TH-OR51](#) **Glycated Albumin and Adverse Clinical Outcomes in Patients with CKD** – Mengyao Tang
- 4:39 p.m. [TH-OR52](#) **Harnessing Kidney Transcriptome Profiles to Predict Rapid Progression of Diabetic Kidney Disease** – Dianne Acoba
- 4:48 p.m. [TH-OR53](#) **FIGARO-BM, a Biomarker Study of FIGARO-DKD, Reveals New Insights into the Mode of Action of Finerenone** – Mario Berger
- 4:57 p.m. [TH-OR54](#) **Renal Effects of Empagliflozin Alone or in Combination with Semaglutide in Albuminuric Type 2 Diabetes: A Randomized, Placebo-Controlled Trial** – Frederik Persson
- 5:06 p.m. [TH-OR55](#) **Effects of Canagliflozin on Renal Oxygenation Evaluated Using Blood Oxygenation Level-Dependent MRI in Patients with Type 2 Diabetes** – Katsuhito Mori
- 5:15 p.m. [TH-OR56](#) **Insulin Resistance, Kidney Outcomes, and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and CKD** – Johannes Smeijer
- 5:24 p.m. [TH-OR57](#) **Single-Nephron Dynamics in Patients with Overt Diabetic Nephropathy** – Akane Miura
- 5:33 p.m. [TH-OR58](#) **Implementation of a Kidney Screening Intervention to Improve Early CKD Detection in Type 2 Diabetes (T2D)** – Margaret Spolnik
- 5:42 p.m. [TH-OR59](#) **Effects of GLP-1 Receptor Agonist Dulaglutide on Profile of Circulating miRNAs Associated with ESKD in Type 2 Diabetes** – Eiichiro Satake
- 5:51 p.m. [TH-OR60](#) **Earlier Intervention in Diabetic Kidney Disease Management Using the In Vitro Diagnostic Test PromarkerD Shows Economic Health Benefits over Current Standard of Care** – Kirsten Peters

Investigations in Polycystic and Tubulointerstitial Kidney DiseasesRoom 105

Moderators: York Pei, Terry Watnick

- 4:30 p.m. [TH-OR61](#) **ApoA4 Mutations Cause Autosomal Dominant Tubulointerstitial Kidney Disease with Medullary Amyloidosis** – Anthony Bleyer
- 4:39 p.m. [TH-OR62](#) **Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Stimulates Autophagy and Restores Mitochondrial Homeostasis to Treat Uromodulin-Associated Nephropathy** – Chuang Li
- 4:48 p.m. [TH-OR63](#) **Inactivation of Ire1alpha Endoribonuclease Domain Slows Down ADPKD in Orthologous Mouse Models** – Rishi Bhardwaj
- 4:57 p.m. [TH-OR64](#) **Role of ER-Mitochondria Connection in the Pathogenesis of ADPKD** – Biswajit Padhy
- 5:06 p.m. [TH-OR65](#) **Organoid Xenograft Model of Polycystic Kidney Disease Reveals Context-Dependent Cross-Talk Between Primary Cilium and Autophagy in Cystogenesis** – Yun Xia
- 5:15 p.m. [TH-OR66](#) **Downregulation of O-GlcNAcylation, a Metabolic Regulator, Attenuates PKD Progression** – Matthew Kavanaugh
- 5:24 p.m. [TH-OR67](#) **Ciliary Exclusion of ARL13B or Loss of Its GEF Activity for ARL3 Suppresses Polycystic Kidney Disease in Mice** – Robert Van Sciver
- 5:33 p.m. [TH-OR68](#) **Deletion of the Circadian Clock Gene Bmal1 in Renal Collecting Ducts Leads to Rapid Cyst Growth in Autosomal Dominant Polycystic Kidney Disease** – Abeda Jamadar
- 5:42 p.m. [TH-OR69](#) **Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease** – Karam Aboudehen
- 5:51 p.m. [TH-OR70](#) **Aberrant Renal Microvascular Remodelling and Impaired Blood Perfusion Occur in the Early Stages of Autosomal Dominant Polycystic Kidney Disease** – Daniyal Jafree

Mechanisms and Single-Cell Transcriptional Profiles in Transplant Rejection and Ischemia Reperfusion Injury..... Room 115

Moderators: Ana Konvalinka, Caroline Lamarche

- 4:30 p.m. **TH-OR71 Live Imaging Coupled with Image-Based Machine Learning Uncovers Potential Drivers and Therapeutic Targets in a Human Model of Ischaemic Reperfusion Injury** – Carmen Cusack
- 4:39 p.m. **TH-OR72 PPAR α , as a Key Determinant of Kidney Size, Revealed by Multi-Omics** – Hiroaki Kikuchi
- 4:48 p.m. **TH-OR73 Spatiotemporal Immune Atlases of Two Gene-Edited, Pig-to-Human Kidney Xenotransplants** – Matthew Cheung
- 4:57 p.m. **TH-OR74 Subpopulations of Injured Proximal Tubular Cells in Allograft Kidneys: Computational Analysis of Available scRNAseq Datasets** – Sylvia da Silva Fernandes
- 5:06 p.m. **TH-OR75 Cold Storage-Mediated p38MAPK Activation: A Potential Contributor of Proteasome Dysfunction and Kidney Damage After Transplantation** – Dinesh Bhattarai
- 5:15 p.m. **TH-OR76 Mechanism of Cold Storage-Mediated Regulation of Heat Shock Proteins in Renal Grafts After Transplantation** – Seongok Lee
- 5:24 p.m. **TH-OR77 Evaluation of Porcine Cell Chimerism and Viral Transmission Using a Preclinical Human Brain-Dead Decedent Model** – Matthew Cheung
- 5:33 p.m. **TH-OR78 The Alteration of Monocyte Subsets and the Early Acute Rejection After Kidney Transplantation** – Jeongin Song
- 5:42 p.m. **TH-OR79 MIF-CD74: A Novel Inflammatory Pathway that Suppresses Allograft-Infiltrating Tregs During Rejection** – Nour Younis
- 5:51 p.m. **TH-OR80 CER-001, a Recombinant HDL, Modulates Ischemia/Reperfusion Injury (IRI) in Hypothermic (HMP) and Normothermic Perfusion (NMP) Solutions Through pAKT/eNOS Activation** – Rossana Franzin

Mechanisms of Hypertension and Cardiorenal Disease: From the Vasculature to the Gut..... Room 108

Moderators: Jennifer Pluznick, Nirupama Ramkumar

- 4:30 p.m. **TH-OR81 Chemogenetic Activation of Pericytes Alters Systemic and Renal Hemodynamics** – Jonathan Nelson
- 4:39 p.m. **TH-OR82 Piezo1 Participates the Mechanosensation of Juxtaglomerular Cells and Regulates Renin Production In Vitro and In Vivo** – Yiming Zhou
- 4:48 p.m. **TH-OR83 Cellular-Level Transcriptomics and Three-Dimensional Imaging for Recruited Renin Cells** – Hiroki Yamaguchi
- 4:57 p.m. **TH-OR84 Identification and Characterization of a Vascular Calcification Mediator Originating in the Adrenal Glands** – Shruti Bhargava
- 5:06 p.m. **TH-OR85 Mechanisms of Vascular Pathology Following Peritonitis in Peritoneal Dialysis Patients and Therapeutic Intervention** – Esra Cetin
- 5:15 p.m. **TH-OR86 Single-Cell Pathological Landscape Analysis of Vascular Calcification in CKD by Imaging Mass Cytometry** – Yuyao Wang
- 5:24 p.m. **TH-OR87 CKD Causes Cardiac Metabolic Remodeling via FGF23 and FGFR4** – Michaela Fuchs
- 5:33 p.m. **TH-OR88 Left Ventricular Systolic Dysfunction in the NBCe1-B/C Knockout Mouse: A Possible Unappreciated Phenotype of Congenital Proximal Renal Tubular Acidosis (pRTA)** – Clayton Brady
- 5:42 p.m. **TH-OR89 Dopamine D4 Receptor Regulates Sodium Chloride Cotransporter in Renal Distal Convoluted Tubules** – Mingzhuo Zhang
- 5:51 p.m. **TH-OR90 Targeted Antibiotic Modulation of the Gut Microbiome Ameliorates Hypertensive Organ Damage** – Moritz Wimmer

Onconeurology and Precision Pharmacology.....Room 107

Moderators: Thomas Nolin, Meghan Sise

- 4:30 p.m. [TH-OR91](#) **Performance of eGFR Equations for Drug Dosing in Kidney Transplant Recipients** – Gregory Hundemer
- 4:39 p.m. [TH-OR92](#) **Performance of Creatinine and Cystatin C-Based Equations Among Patients with Hematological or Solid Cancers: Real-World Data from a Clinical Cohort** – Silvia Titan
- 4:48 p.m. [TH-OR93](#) **MTX652, a Novel Selective USP30 Inhibitor for the Treatment of AKI: Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections** – Pau Aceves
- 4:57 p.m. [TH-OR94](#) **Treatment of Diuretic Resistance with a Kappa Opioid Agonist, an Inhibitor of Central Vasopressin Secretion** – Ashlyn Anderson
- 5:06 p.m. [TH-OR95](#) **Cystatin C-Defined AKI in Children Treated with Cisplatin** – Erin Hessey
- 5:15 p.m. [TH-OR96](#) **SGLT2 Inhibitor Protects from Repeated Low-Dose Cisplatin-Induced Chronic Kidney Damage** – Dianet Sanchez Vega
- 5:24 p.m. [TH-OR97](#) **Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes** – Leyi Gu
- 5:33 p.m. [TH-OR98](#) **Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis** – Thomas Mavrakanas
- 5:42 p.m. [TH-OR99](#) **Ondansetron and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis** – Sherin Ismail
- 5:51 p.m. [TH-OR100](#) **Safety Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Diabetes Mellitus and Cancer** – Aisha Shaikh

Research Advances in Bone and Mineral Metabolism.....Room 111

Moderators: Rosa Moyses, Pablo Urena Torres

- 4:30 p.m. [TH-OR31](#) **PI3K/AKT/mTOR Pathway Regulates Renal Expression of Klotho** – Aurora Perez-Gomez
- 4:39 p.m. [TH-OR32](#) **Spatial Genomics Localized Nephron Segment-Specific FGF23 and CKD Klotho-Dependent and -Independent Transcriptional Reprogramming** – Lainey Hibbard
- 4:48 p.m. [TH-OR33](#) **Role of miR-122 on FGF23 Cleavage** – Jane Thomas
- 4:57 p.m. [TH-OR34](#) **Direct Effects of FGF23 on Osteoblasts Contribute to Bone Defects in Dmp1KO Mice Independently of Phosphate** – Dominik Kentrup
- 5:06 p.m. [TH-OR35](#) **The Essential Roles of miRNA and mTORC1 in Parathyroid Function and in Maintaining Parathyroid Glands in the Adult** – Alia Hassan
- 5:15 p.m. [TH-OR36](#) **The Role of Osteopontin and Osteocyte-Derived Factors in Secondary Hyperparathyroidism-Induced Muscle Dystrophy** – Eduardo Duque
- 5:24 p.m. [TH-OR37](#) **Bone Quality in Uremic Patients: Interactions Between Parathyroid Hormone (PTH) and Propionic Acid** – Elizabeth Kermgard
- 5:33 p.m. [TH-OR38](#) **Calcium Isotope Ratios in Serum: A Novel Biomarker of Bone and Vessel Calcium Balance in Patients on Dialysis** – Rukshana Shroff
- 5:42 p.m. [TH-OR39](#) **Role of Plasma Inorganic Pyrophosphate in Calciphylaxis: A Prospective Study** – Api Chewcharat
- 5:51 p.m. [TH-OR40](#) **Loss of Renal Tubular Claudin-2 Increases Renal Calcification and Urinary Stone Disease** – Muthuvel Jayachandran

Poster Sessions

Thursday, November 2 | Exhibit Hall C

Poster Topics	Board #s
NIH/NIDDK and Informational Posters – I.....	INFO01–INFO17
AI, Digital Health, Data Science – I.....	001–049
AKI: Liver Disease, Nephrotoxicity, Novel Therapeutics.....	050–078
AKI: Mechanisms – I.....	079–126
Bone and Mineral Metabolism: CKD-MBD Updates.....	127–165
Diabetic Kidney Disease: Clinical – I.....	166–194
Hypertension and CVD: Clinical – I.....	195–244
Hemodialysis: Volume, Metabolic Complications, Clinical Outcomes.....	245–304
Home Dialysis – I.....	305–354
Fluid, Electrolyte, Acid-Base Disorders: Clinical – I.....	355–400
Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis.....	401–445
Genetic Diseases: Glomerulopathies – I.....	446–487
Pediatric Nephrology – I.....	488–529
Glomerular Diseases: From Inflammation to Fibrosis – I.....	530–579
Glomerular Diseases: Clinical and Epidemiologic Studies.....	580–636
Glomerular Diseases: Epidemiology and Case Reports.....	637–691
Glomerular Diseases: Case Reports.....	692–732
Glomerular Diseases: Podocyte Biology – I.....	733–791
Pathology and Lab Medicine – I.....	792–819
Transplantation: Clinical – I.....	820–869
Transplantation: Donation and Access.....	870–911
Health Maintenance, Nutrition, Metabolism – I.....	912–945
Anemia in CKD: Risk Factors, Practice Patterns, Therapies.....	946–988
CKD Epidemiology, Risk Factors, Prevention – I.....	989–1031
CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors.....	1032–1087
COVID-19 – I.....	1088–1112
Late-Breaking Clinical Trials.....	1113–TBD

**Abstract details are available in the Kidney Week app
and at www.asn-online.org/kidneyweek.**



Welcome Reception
Thursday, November 2
6:00–7:00 p.m.
Exhibit Hall C

The Welcome Reception is supported by

calliditas
THERAPEUTICS



DIGITAL PATHOLOGY ROOM ROOM 110

You are invited to a hands-on review session of all the digital slides from the **Renal Biopsy: Clinical Correlations** session vignettes prior to Saturday, November 4, when the final diagnoses are discussed in-depth and answers to the cases are distributed. Biopsy materials are available with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Pathology Room; however, space is limited and available on a first-come, first-served basis.

Thursday

November 2

9:30 a.m. — 4:30 p.m.

Friday

November 3

9:30 a.m. — 4:30 p.m.

ASN thanks the Renal Pathology Society for assistance with the Renal Biopsy session and the Digital Pathology Room.

The Digital Pathology Room is supported by



DAY-AT-A-GLANCE

Friday, November 3

6:45 a.m. – 7:45 a.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 6:30 a.m.

Radiofrequency Renal Denervation: The Next Frontier for Difficult-to-Control Hypertension..... Salon I
Regulating the Regulator: Exploring the Therapeutic Landscape for
Complement-Mediated Kidney Diseases..... Salon D

8:00 a.m. – 9:30 a.m.

Plenary: Peters Award, Seldin Award and Address, State-of-the-Art Lecture..... Hall A

9:30 a.m. – 2:30 p.m.

Morning Break (9:30 a.m. – 10:00 a.m.)..... Exhibit Hall C
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)..... Exhibit Hall C
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)..... Exhibit Hall C

10:00 a.m. – 1:45 p.m.

Exhibitor Spotlights Exhibit Hall C
Please see pages 10-11 for the schedule and topics.

10:30 a.m. – 12:30 p.m.

Clinical Practice Sessions

Calming the Waters: Managing Hyponatremia in Different Clinical Settings..... Room 103
Climbing Up and Down the AKI Mountain: Navigating Data, Divides,
Diagnostics, and Dialysis..... Room 201
Clinical Stone Disease: Tools and Risk Factors, with the Coburn Endowed Lectureship Room 119
Home Dialysis Quiz and Questionnaire Room 113
Implementation of Novel AKI Biomarkers in Clinical Practice Ballroom B
Leave No Kidney Behind: Optimizing Utilization of Deceased and Living Donor Kidneys..... Room 115
New Insights into Achieving Meaningful Weight Loss in CKD,
with the Rose Endowed Lectureship..... Room 108

Translational Sessions

Collagen IV Conundrums: Genetic Variants and Clinical Management Room 204
Heart-Kidney Cross-Talk: How Should I Be Approaching Cardiorenal Disease? Ballroom A
Insights into Liver-Kidney Cross-Talk Room 118

Oral Abstract Session

High-Impact Clinical Trials: Part 1..... Hall A

Other Events

Advancing Health Equity for All: Addressing SDoH in Access to Transplant..... Room 109
Fellows-in-Training Bowl: Semi-Finals and Finals..... Exhibit Hall C

12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown Level 5, Grand Ballroom)

Doors open at 12:30 p.m.

Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities..... Salon L
Hyperkalemia in Diabetes and Heart Failure: Optimizing Management to Mitigate Risk..... Salon I
IgA Nephropathy: Proteinuria, Vasoactive Peptides, and the Evolving Treatment Landscape Salon A
What's Complement Got to Do with It? ANCA Vasculitis and the Complement System..... Salon D

1:00 p.m. – 2:00 p.m.

Top Trainee Posters..... Exhibit Hall C

2:00 p.m. – 4:00 p.m.**Basic/Clinical Science Sessions**

Bioenergetics of Diabetic Kidneys, with the Brenner Endowed Lectureship	Room 120
Carving New Paths for AKI Therapy: What's on the Horizon	Room 108
Cilia Proteins in Development and Diseases.....	Room 107
Higher and Higher Resolution: Advances in Single-Cell or -Omics Studies in CKD.....	Ballroom A
Innovative Immunosuppression and Monitoring Strategies in Pediatric Kidney Transplantation	Room 105
Microvascular Inflammation in Kidney Transplantation: An Unresolved Dilemma.....	Room 109
Pragmatic Clinical Trials as Means to Update Clinical Practice in CKD-MBD.....	Room 119
Translation of Genetic Discoveries in Nephrotic Syndrome, with the Winn Endowed Lectureship.....	Room 204
Water Channels in the Kidneys and Beyond.....	Room 111
Xenotransplantation Is on the Horizon.....	Room 115

Clinical Practice Sessions

Case Studies in Glomerular Diseases 2023.....	Ballroom B
Environmental Health and the Kidneys.....	Room 114 (Nutter Theatre)
Managing Patients on Dialysis: How Can We Improve Care?	Room 113
Nephrocardiology Care Models: From Idea to Implementation.....	Room 118

Translational Sessions

Future of Data Science in Kidney Medicine and Research.....	Room 103
Onconephrology: Focus on Hematology.....	Room 201

Special Session

Winning Team: The Nephrology Workforce for the 21st Century	Room 121
---	----------

4:00 p.m. – 4:30 p.m.

Afternoon Break.....Foyers of Rooms 201/204, 108, 118

4:30 p.m. – 6:00 p.m.**Clinical Practice Sessions**

Controversies in C3 Glomerulopathy.....	Room 201
Drug Dosing in Advanced CKD and ESKD.....	Room 113
Serving the Underserved: Improving Kidney Health in Underserved Populations	Room 204

Translational Session

Dietary and Metabolic Interventions in ADPKD: The Rationale and Clinical Benefit.....	Room 114 (Nutter Theatre)
--	---------------------------

Oral Abstract Sessions

AKI Prediction and Assessment: Traditional and Novel Tools	Room 118
Development, Organoids, and Genetic Models of Kidney Diseases	Room 105
Fluid, Electrolyte, and Acid-Base Disorders: Basic Research.....	Room 111
How Sweet It Is: Basics of Diabetic Kidney Disease	Room 121
Interventions to Reduce CKD Progression	Room 119
Kidney Pathology: From Classic Clinicopathologic Studies to Computational Pathology.....	Room 109
Kidney Transplantation: Biomarkers, New and Old.....	Room 115
Managing the Many Facets of Home Dialysis.....	Room 120
Navigating a Path to Diversity and Equity in Kidney Health	Room 107
Novel Clinical Impacts on Cardiorenal Disease	Room 103
Podocytopathy: Novel Insights and Emerging Therapeutic Targets	Room 108

Friday, November 3, 6:45 a.m. – 7:45 a.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 6:30 a.m. Breakfast is provided.

Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Radiofrequency Renal Denervation: The Next Frontier for Difficult-to-Control Hypertension Salon I

Support is provided by an educational grant from Medtronic.

- 6:45 a.m. **Introduction** – Jennifer Pollock (Moderator)
- 6:55 a.m. **Interpreting the Renal Denervation Literature: Mechanisms, Safety, and Effectiveness** – Raymond Townsend
- 7:15 a.m. **Practical Approaches to Renal Denervation: Establishing a Program and Optimizing Patient Selection** – Michael Weber
- 7:35 a.m. **Questions and Answers**

Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases..... Salon D

Support is provided by an educational grant from Novartis Pharmaceuticals Corporation.

- 6:45 a.m. **Introduction** – Duvuru Geetha (Moderator)
- 6:55 a.m. **Complement-Mediated Kidney Diseases: Novel Insights and New Possibilities** – Andrew Bomback
- 7:15 a.m. **New Horizons: Considering the Evolving Therapeutic Landscape for IgA Nephropathy** – Chee Kay Cheung
- 7:35 a.m. **Questions and Answers**

Friday, November 3, 8:00 a.m. – 9:30 a.m.

Plenary..... Hall A

The Donald W. Seldin Young Investigator Award is cosponsored by ASN and the American Heart Association Council on the Kidney in Cardiovascular Disease.

- 8:10 a.m. **John P. Peters Award** – Katherine Tuttle
- 8:20 a.m. **Donald W. Seldin Young Investigator Award and Address “Human Kidney Organoids for Disease Modeling and Regeneration”** – Benjamin Freedman
- 8:50 a.m. **State-of-the-Art Lecture “How Do You Feel? The Molecules that Sense Touch”** – Ardem Patapoutian

Friday, November 3, 10:30 a.m. – 12:30 p.m.

Calming the Waters: Managing Hyponatremia in Different Clinical Settings..... Room 103

Moderators: Roger Rodby, Amy Yau

- 10:30 a.m. **Patients with Severe Hyponatremia in the Intensive Care Unit** – Helbert Rondon Berrios
- 11:00 a.m. **Patients with Chronic SIAD in the Office** – Annabelle Warren
- 11:30 a.m. **Patients with Cirrhosis and Hyponatremia** – Juan Carlos Velez
- 12:00 p.m. **Patients with Heart Failure and Hyponatremia** – Frederik Verbrugge

Climbing Up and Down the AKI Mountain: Navigating Data, Divides, Diagnostics, and Dialysis Room 201

ASN thanks the ASN AKINow Recovery/Post-AKI Workgroup and Public Awareness and Education Workgroup for assistance with this session.

Support is provided by an educational grant from 3iveLabs.

Moderators: Anitha Vijayan, Ron Wald

Patient Commentator: Marla Levy

- 10:30 a.m. **Raising Awareness: Impact of AKI on Outcomes** – Michael Heung
- 11:00 a.m. **Bridging the Divide from Hospital to Home: Challenges and Opportunities** – Edward Siew
- 11:30 a.m. **Another Urinary Biomarker for AKI? A Discussion of CCL14** – Melanie Meersch
- 12:00 p.m. **Set Them Free: How to Liberate AKI-D Survivors** – Chi-yuan Hsu

Clinical Stone Disease: Tools and Risk Factors, Including the Jack W. Coburn, MD, Endowed Lectureship Room 119

ASN gratefully acknowledges Amgen for support of the Coburn Endowed Lectureship.

Moderators: Sonia Fargue, Alan Pao

- 10:30 a.m. **Who Is at Risk for Recurrent Stone Disease?** – Pietro Manuel Ferraro
- 11:00 a.m. **Stone Prevention in Patients with Bowel Disease: The Jack W. Coburn, MD, Endowed Lectureship** – Elaine Worcester
- 11:30 a.m. **Nephrolithiasis in Kidney Transplantation** – Mira Keddiss
- 12:00 p.m. **A (Warming) World in a Grain of Sand: Impact of Societal and Environmental Change on Stone Risk** – David Goldfarb

Home Dialysis Quiz and Questionnaire Room 113

ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Joel Glickman, Rajnish Mehrotra

- 10:30 a.m. **Clinical Advantages of More Frequent Dialysis** – Eric Weinhandl
- 11:00 a.m. **The Right Balance: Individualizing Peritoneal Dialysis Prescriptions** – Jeffrey Perl
- 11:30 a.m. **Getting Creative: Finding the Right Prescription for Home Hemodialysis** – Brigitte Schiller
- 12:00 p.m. **Hot and SPICEy: Antimicrobial Resistance in Peritoneal Dialysis Infections from Prevention to Treatment** – Sharon Nessim

Implementation of Novel AKI Biomarkers in Clinical PracticeBallroom B

Moderators: Rajit Basu, Blaithin McMahon

- 10:30 a.m. **How to Use Advanced Test Systems (TIMP2-IGFBP7) Testing in Clinical Practice** – Jay Koyner
- 11:00 a.m. **How to Use Neutrophil Gelatinase-Associated Lipocalin (NGAL) Testing in Clinical Practice** – Jean Maxime Cote
- 11:30 a.m. **How to Use Functional AKI Biomarkers in Clinical Practice** – Marlies Ostermann
- 12:00 p.m. **How to Use Biomarkers of Drug-Induced Kidney Injury in Clinical Drug Development** – Vishal Vaidya

Leave No Kidney Behind: Optimizing Utilization of Deceased and Living Donor Kidneys..... Room 115

ASN thanks the ASN Diversity, Equity, and Inclusion Committee for assistance with this session.

Moderators: Vineeta Kumar, Adetokunbo Taiwo

- 10:30 a.m. **Reflections of a Two-Time Kidney Transplant Recipient** – Nichole Jefferson
- 11:00 a.m. **Shared Decision Making in Deceased Donor Kidney Allocation** – Sumit Mohan
- 11:30 a.m. **A Living Kidney Donor's Experience: Barriers and Opportunities** – Martha Gershun
- 12:00 p.m. **Engaging Friends and Families to Enhance Living Donor Kidney Transplant Among African Americans** – L. Ebony Boulware

New Insights into Achieving Meaningful Weight Loss in CKD, Including the Burton D. Rose, MD, Endowed Lectureship Room 108

ASN gratefully acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess Medical Center Department of Medicine Foundation, the Rose Family, and several of Dr. Rose's colleagues for supporting this lectureship.

Moderators: Allon Friedman, Sarah Schraubert

- 10:30 a.m. **Hypobaric Hypoxia and Its Cardiorenal Benefit for Weight Loss: The Burton D. Rose, MD, Endowed Lectureship** – Biff Palmer
- 11:00 a.m. **Ketogenic Metabolic Therapies for CKD** – Johannes Kovarik
- 11:30 a.m. **Bariatric Surgery: Mechanism and Efficacy in CKD** – Aleksandra Kukla
- 12:00 p.m. **Pharmacologic Mechanisms of Weight Loss to Include SGLT2 Inhibitors and GLP1/GIP Agonists** – Alexander Chang

Collagen IV Conundrums: Genetic Variants and Clinical Management..... Room 204

ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Roser Torra.

Session support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Jan Halbritter, Judith Savige

- 10:30 a.m. **When to Consider Testing Collagen Genes in General Nephrology Practice** – Thomas Oates
- 11:00 a.m. **How to Interpret Collagen IV Genetic Results** – Moumita Barua
- 11:30 a.m. **Do All Collagen Variants Cause Glomerular Disease?** – Roser Torra
- 12:00 p.m. **Current and Emerging Therapies: How, When, and Who to Treat with a Collagen Variant** – Michelle Rheault

Heart-Kidney Cross-Talk: How Should I Be Approaching Cardiorenal Disease? Ballroom A

Moderators: Mark Sarnak, Wolfgang Winkelmayer

- 10:30 a.m. **Kidney Biomarkers to Guide Diuresis in Patients with Acute Decompensated Heart Failure** – Jeffrey Testani
- 11:00 a.m. **Implementation of a New Era of Goal-Directed Medical Therapy for Patients with Cardiorenal Disease** – Katherine Tuttle
- 11:30 a.m. **Direct Oral Anticoagulants in Patients Treated with Dialysis: Where Are We Now?** – Glenn Chertow
- 12:00 p.m. **How Should We Screen for CVD in Patients with CKD?** – David Charytan

Insights into Liver-Kidney Cross-Talk..... Room 118

Moderators: Beom Seok Kim, Ashita Tolwani

- 10:30 a.m. **Liver-Kidney Connection in Chronic Liver Disease** – Florence Wong
- 11:00 a.m. **Non-Alcoholic Fatty Liver Disease as a Driver of CKD** – Mazen Nouredin
- 11:30 a.m. **Liver Biomarkers and Kidney Outcomes** – Chan-Young Jung
- 12:00 p.m. **CKD in Liver Transplant Recipients** – Maria Ajaimy

Friday, November 3, 10:30 a.m. – 12:30 p.m.

High-Impact Clinical Trials: Part 1..... Hall A

Please check the Kidney Week app or the ASN website for session details.

Advancing Health Equity for All: Addressing SDoH in Access to Transplant Room 109

Note: Continuing education credits are not being offered for this activity.

Fellows-in-Training Bowl: Semi-Finals and FinalsFutures Theater - Exhibit Hall C

Support is provided by Calliditas Therapeutics.

Note: Continuing education credits are not being offered for this activity.

Friday, November 3, 12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 12:30 p.m. Lunch is provided.

Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities..... Salon L

Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.

12:45 p.m. **Introduction** – Andrew Davenport (Moderator)

12:55 p.m. **Diagnosing and Monitoring HRS-AKI: Present and Future** – Luis Juncos

1:15 p.m. **How Hepatologists Think About HRS-AKI Treatment in 2023** – Guadalupe Garcia-Tsao

1:35 p.m. **Questions and Answers**

Hyperkalemia in Diabetes and Heart Failure: Optimizing Management to Mitigate Risk.... Salon I

Support is provided by an educational grant from AstraZeneca.

12:45 p.m. **Introduction** – Joanna Hudson (Moderator)

12:55 p.m. **Hyperkalemia in the Patient with Diabetic Kidney Disease** – David Mount

1:15 p.m. **Hyperkalemia in the Patient with Heart Failure** – Angela Yee Moon Wang

1:35 p.m. **Questions and Answers**

IgA Nephropathy: Proteinuria, Vasoactive Peptides, and

the Evolving Treatment Landscape.....Salon A

Support is provided by an educational grant from Travele Therapeutics, Inc.

12:45 p.m. **Introduction** – Daniel Cattran (Moderator)

12:55 p.m. **Endothelin-1 Effects on Glomerular Filtration, Kidney Inflammation, and Damage** – Carmen De Miguel

1:15 p.m. **Emerging Therapeutic Options in IgA Nephropathy** – Pietro Canetta

1:35 p.m. **Questions and Answers**

What's Complement Got to Do with It? ANCA Vasculitis and the Complement System Salon D

This activity is supported by educational funding provided by Amgen.

12:45 p.m. **Introduction** – Ladan Zand (Moderator)

12:55 p.m. **The Pathophysiology of ANCA Vasculitis and the Role of Complement** – Adrian Schreiber

1:15 p.m. **Treatment and Management of ANCA Vasculitis** – Michael Walsh

1:35 p.m. **Questions and Answers**

Bioenergetics of Diabetic Kidneys, Including the Barry M. Brenner, MD, Endowed Lectureship..... Room 120

ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Brenner Endowed Lectureship.

Moderators: Luigi Gnudi, Krisztian Stadler

- 2:00 p.m. **Toward Solutions! Pro-Resolving Lipid Mediators of Metabolism and Inflammation: The Barry M. Brenner, MD, Endowed Lectureship – Catherine Godson**
- 2:30 p.m. **Mitochondria and Sterile Inflammation in Diabetic Kidney Disease – Sandra Merscher**
- 3:00 p.m. **Mitochondrial Enzymes, Like PKM2, Offering Protection Against Diabetic Kidney Disease – George King**
- 3:30 p.m. **Mitochondrial Targets in Diabetic Kidney Disease – Melinda Coughlan**

Carving New Paths for AKI Therapy: What's on the Horizon..... Room 108

Moderators: Neil Hukriede, Motoko Yanagita

- 2:00 p.m. **Controlling Cell Death – Andreas Linkermann**
- 2:30 p.m. **AKI and Krüppel-Like Transcription Factors – Sian Piret**
- 3:00 p.m. **Endothelial Hypoxic Metabolic Reprogramming in Kidney Injury and Repair – Pinelopi Kapitsinou**
- 3:30 p.m. **Non-Coding RNA in AKI – Laura Denby**

Cilia Proteins in Development and Diseases..... Room 107

Moderators: Moe Mahjoub, Robin Maser

- 2:00 p.m. **Visualizing Cilia Function in Kidney Injury and Diseases – Bradley Yoder**
- 2:30 p.m. **Extracellular Protease Modulation of the Cilium Transition Zone in Kidney Development and Diseases – Sumeda Nandadasa**
- 3:00 p.m. **Polycystin-1's C-Terminal Tail Suppresses Cystic Disease – Michael Caplan**
- 3:30 p.m. **Ciliary Disease and Potential Therapeutic Mechanisms – Sophie Saunier**

Higher and Higher Resolution: Advances in Single-Cell or -Omics Studies in CKD..... Ballroom A

Moderators: Hiroki Kobayashi, Marcus Pezzolesi

- 2:00 p.m. **Single-Cell Modalities – Parker Wilson**
- 2:30 p.m. **Epigenetics in CKD – Kaori Hayashi**
- 3:00 p.m. **Tissue Proteome of the Diabetic Kidneys – Daigoro Hirohama**
- 3:30 p.m. **Circulating Proteomics and Protein Biomarkers of Diabetic Kidney Disease – Ruth Dubin**

Innovative Immunosuppression and Monitoring Strategies in

Pediatric Kidney Transplantation..... Room 105

Moderators: Sandra Amaral, Rachel Engen

- 2:00 p.m. **Past, Present, and Future of Immunosuppression in Pediatric Kidney Transplantation – Eileen Chambers**
- 2:30 p.m. **Novel Desensitization and Treatment Strategies for Antibody-Mediated Rejection in Children – Dechu Puliyaanda**
- 3:00 p.m. **Is HLA Eplet Matching a Viable Way to Improve Clinical Outcomes in Pediatric Kidney Transplantation? – Anat Tambur**
- 3:30 p.m. **Costimulation Blockade in Pediatric Kidney Transplantation: The ADVANTAGE Trial – David Briscoe**

Friday, November 3, 2:00 p.m. – 4:00 p.m.

Microvascular Inflammation in Kidney Transplantation: An Unresolved Dilemma..... Room 109

ASN thanks the Renal Pathology Society for assistance with this session.

Moderators: Surya Seshan, Kristen Tomaszewski

- 2:00 p.m. **Mechanisms of Microvascular Inflammation in the Kidney Allograft** – Dany Anglicheau
- 2:30 p.m. **Clinical Significance of Microvascular Inflammation: Are Donor-Specific Antibodies Required?** – Chul Woo Yang
- 3:00 p.m. **Gene Expression Profiling in Microvascular Inflammation** – Ivy Rosales
- 3:30 p.m. **Pathologic Scoring of Microvascular Inflammation: Importance in Diagnosis and Prognosis in Antibody-Mediated Rejection** – Mark Haas

Pragmatic Clinical Trials as Means to Update Clinical Practice in CKD-MBD Room 119

Moderators: Orlando Gutierrez, Michal Melamed

- 2:00 p.m. **Overview of Prior Pragmatic Clinical Trials in Dialysis and Applications to CKD-MBD** – Andrea Cowan
- 2:30 p.m. **Overview of the HiLo Trial** – Daniel Edmonston
- 3:00 p.m. **Overview of the PHOSPHATE Trial** – Ron Wald
- 3:30 p.m. **Rationale for a Pragmatic Clinical Trial for Management of Secondary Hyperparathyroidism** – Julia Scialla

Translation of Genetic Discoveries in Nephrotic Syndrome, Including the Michelle P. Winn, MD, Endowed Lectureship Room 204

ASN gratefully acknowledges Duke University School of Medicine, the school's Division of Nephrology, and several individuals for support of the Winn Endowed Lectureship.

Session support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Gentzon Hall, Daria Ilatovskaya

- 2:00 p.m. **Illuminating the Genetics of Nephrotic Syndrome** – Krzysztof Kiryluk
- 2:30 p.m. **MUC'ing Things Up: Exploring MUC1 as a Therapeutic Target in Proteinuric Kidney Disease** – Anna Greka
- 3:00 p.m. **Podocyte Lipid Handling as a Therapeutic Target for Collagenopathy: The Michelle P. Winn, MD, Endowed Lectureship** – Alessia Fornoni
- 3:30 p.m. **Emerging Therapeutics for COVID-19-Associated Nephropathy (COVAN) and HIV-Associated Nephropathy (HIVAN) in Patients with APOL1 Renal Risk Variants** – Opeyemi Olabisi

Water Channels in the Kidneys and Beyond Room 111

Moderators: James McCormick, Cesar Romero

- 2:00 p.m. **YAP1 Controls the Expression of Collecting Duct Aquaporins and Water Homeostasis** – Yin Xia
- 2:30 p.m. **AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis** – Olivier Devuyst
- 3:00 p.m. **Ribosomal S6 Kinase (RSK): A New Player in the Regulation of AQP2 Intracellular Trafficking** – Pui Susan Cheung
- 3:30 p.m. **Estrogen Regulates Aquaporin-2 in the Kidneys** – Rikke Norregaard

Xenotransplantation Is on the Horizon Room 115

Moderators: Reza Abdi, Xun-Rong Luo

- 2:00 p.m. **First Pig to Human Cardiac Xenotransplantation: A Success?** – Muhammad Mohiuddin
- 2:30 p.m. **First Pig to Human Kidney Xenotransplantation** – Jayme Locke
- 3:00 p.m. **Progress in Kidney Xenotransplantation: Are We Ready for Clinics?** – Andrew Adams
- 3:30 p.m. **Scientific Approaches That Address Compatibility and Immunosuppression for Xenotransplanted Kidneys** – David Cooper

Case Studies in Glomerular Diseases 2023Ballroom B

Support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Ingeborg Bajema, Brad Rovin

- 2:00 p.m. **Case 1** – Kirk Campbell
- 2:30 p.m. **Case 2** – Katherine Dell
- 3:00 p.m. **Case 3** – Koyal Jain
- 3:30 p.m. **Case 4** – Arvind Nagra

Environmental Health and the Kidneys Room 114 (Nutter Theatre)

Moderators: Jason Watts, Daniel Weiner

- 2:00 p.m. **Emergency Preparedness in Nephrology Care** – Myra Kleinpeter
- 2:30 p.m. **Climate Change: What to Know as a Nephrologist** – Sarah Young
- 3:00 p.m. **Kidney Health in Agricultural Workers** – Marc De Broe
- 3:30 p.m. **Use of Water in Dialysis and Its Impact on the Environment** – Suzanne Watnick

Managing Patients on Dialysis: How Can We Improve Care? Room 113

Moderators: Rebecca Schmidt, Carmine Zoccali

- 2:00 p.m. **Potential Hemodialysis Ultrafiltration Rate Warning Levels: How Best to Scale These to Body Size** – John Daugirdas
- 2:30 p.m. **Keys to Success in Managing Vascular Access in Dialysis Patients** – Vandana Niyyar
- 3:00 p.m. **Vaccinations in the Dialysis Unit: Integrating the Patient Perspective into Processes and Practice** – Liz McNamara
- 3:30 p.m. **Uremic Pruritus: Recent Advances in Management** – Tariq Shafi

Nephrocardiology Care Models: From Idea to Implementation Room 118

Moderators: Vivek Bhalla, Janani Rangaswami

- 2:00 p.m. **Pragmatic Approaches of Building a Nephrocardiology Service in the United States** – Jacob Stevens
- 2:30 p.m. **Innovations in Clinical Care, Education, and Research through Nephrocardiology Subspecialization: A Nephrology Perspective** – Nisha Bansal
- 3:00 p.m. **Nephrocardiology Services as a Path to Improving Patient Outcomes: A Cardiology Perspective** – Conrad Macon
- 3:30 p.m. **International Perspectives and Opportunities to Build Cardioneephrology Subspecialization** – Liam Plant

Friday, November 3, 2:00 p.m. – 4:00 p.m.

Winning Team: The Nephrology Workforce for the 21st Century..... Room 121

Moderators: Jane Davis, Mitchell Rosner

- 2:00 p.m. **Advanced Practice Providers' Role in Nephrology in 2023** – Kim Zuber
- 2:30 p.m. **Advocacy and Policy: What Can Nephrologists and National Organizations Do?** – Carmen Cervantes
- 3:00 p.m. **Current Landscape and Needs of the Nephrology Workforce** – Eleanor Lederer
- 3:30 p.m. **Mentoring the Next Generation of Nephrologists** – Samira Farouk

Future of Data Science in Kidney Medicine and Research Room 103

Moderators: Meredith McAdams, Shina Menon

- 2:00 p.m. **AI Today and Tomorrow in Medicine** – Karandeep Singh
- 2:30 p.m. **Finding and Defining Kidney Phenotypes in the Electronic Health Record** – Adriana Hung
- 3:00 p.m. **Coding in Data Science: Addressing Issues of Transparency, Reproducibility, and Public Availability** – Girish Nadkarni
- 3:30 p.m. **The "Nudge" in Clinical Practice: Aligning Patients and Providers for Data-Driven Medicine** – M. Kit Delgado

Onconeurology: Focus on Hematology..... Room 201

Moderators: Ala Abudayyeh, Claude Bassil

- 2:00 p.m. **Thrombotic Microangiopathy: Drugs and Cancer** – Nelson Leung
- 2:30 p.m. **Renal Complications from Lymphomas and Leukemia: Indolent or Aggressive** – Anushree Shirali
- 3:00 p.m. **Light Chain-Related Kidney Injury: Light Chain Tubulopathy and Cast Nephropathy** – Sheron Latcha
- 3:30 p.m. **Kidney Involvement from AL Amyloidosis: Diagnosis and Treatment** – Priya Deshpande

Friday, November 3, 4:30 p.m. – 6:00 p.m.

Controversies in C3 Glomerulopathy..... Room 201

ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Hans Anders. Session support is provided by an educational grant from Travençolo Therapeutics, Inc.

Moderators: Joshua Thurman, Marina Vivarelli

- 4:30 p.m. **What Is C3 Glomerulopathy and What Is It Not?** – Andrew Bomback
- 4:50 p.m. **Drivers of C3 Glomerulopathy** – Hans Anders
- 5:10 p.m. **Role of Biomarkers in C3 Glomerulopathy** – Veronique Fremeaux Bacchi
- 5:30 p.m. **Standard Immune Suppression and Targeted Therapeutics in C3 Glomerulopathy** – Carla Nester

Drug Dosing in Advanced CKD and ESKD Room 113

Moderators: Swapnil Hiremath, Talat Alp Ikizler

- 4:30 p.m. **Drug Dosing in Kidney Diseases and Dialysis: Factors That Affect Drug Clearance** – Linda Awdishu
- 4:50 p.m. **Thiazide Diuretics in Advanced CKD and Dialysis: Are They Effective?** – Rajiv Agarwal
- 5:10 p.m. **Remnant Kidneys Can Still Secrete: Implications on Drug Dosing** – Catherine Yeung
- 5:30 p.m. **KDIGO Guidelines: Prescribing and Deprescribing Drugs in CKD** – Rasheeda Hall

Serving the Underserved: Improving Kidney Health in Underserved Populations..... Room 204

Moderators: Flor Alvarado, Kalani Raphael

- 4:30 p.m. **Kidney Diseases in Incarcerated Populations** – Laura Maursetter
- 4:50 p.m. **Relationship Between CKD and Psychiatric Illness** – Clodagh Cogley
- 5:10 p.m. **Understanding the Burden and Risk of Kidney Diseases in Asian-American Populations** – Leslie Wong
- 5:30 p.m. **Culture-Centered Approaches to Reducing Health Disparities in Indigenous Populations** – Vallabh Shah

Dietary and Metabolic Interventions in ADPKD:

The Rationale and Clinical Benefit Room 114 (Nutter Theatre)

Moderators: Meyeon Park, Ronald Perrone

- 4:30 p.m. **Biological Basis for Metabolic Treatment of ADPKD: Increased Aerobic Glycolysis (Warburg Effect)** – Maria Irazabal
- 4:50 p.m. **Dietary Protein, Immune Cells, and ADPKD Progression** – Takamitsu Saigusa
- 5:10 p.m. **Ketogenic Diet and ADPKD** – Roman-Ulrich Mueller
- 5:30 p.m. **Targeting Adiposity and Caloric Restriction in ADPKD** – Kristen Nowak

Oral Abstract Sessions

AKI Prediction and Assessment: Traditional and Novel Tools Room 118

Moderators: Rolando Claire-Del Granado, Etienne Macedo

- 4:30 p.m. **FR-OR01 AKI Is Associated with Long-Term Decline in Cognitive Function at 3 Years: ASSESS-AKI Study** – Pavan Bhatraju
- 4:39 p.m. **FR-OR02 AKI, Glomerulonephritis, and Tubulointerstitial Nephritis Following Vaccination: VigiBase Analysis** – Soo-Young Yoon
- 4:48 p.m. **FR-OR03 Use of a Recurrent Neural Network to Predict Development of Nephrotoxic AKI in Adults** – Benjamin Griffin
- 4:57 p.m. **FR-OR04 Genome-Wide Association Study of Hospitalized AKI** – Edward Siew
- 5:06 p.m. **FR-OR05 Machine Learning-Guided Novel Subphenotypes of Sepsis-Associated Persistent AKI** – Wonsuk Oh
- 5:15 p.m. **FR-OR06 Arterial Stiffness and AKI in the Atherosclerosis Risk in Communities (ARIC) Study** – Ester Oh
- 5:24 p.m. **FR-OR07 Noninvasive Identification of Acute Tubular Injury Using Plasma Proteomics** – Insa Schmidt
- 5:33 p.m. **FR-OR08 AKI Diagnostic Accuracy and Implications of AKI Baseline Creatinine (ABC) vs. Other Baseline Creatinine Estimating Equations** – Erica Bjornstad
- 5:42 p.m. **FR-OR09 Vancomycin-Tacrolimus Combination Increases AKI Risk in Post-Hematopoietic Stem Cell Transplantation (HSCT) Patients** – Tuisha Gupta
- 5:51 p.m. **FR-OR10 Heart Failure with Preserved Ejection Fraction (HFpEF) vs. Heart Failure with Reduced Ejection Fraction (HFrEF) After AKI** – Bethany Birkelo

Development, Organoids, and Genetic Models of Kidney Diseases Room 105

Moderators: Nils Lindström, Kyle McCracken

- 4:30 p.m. [FR-OR11](#) **Role of Biomechanics in the Regulation of Ureteric Bud Branching Morphogenesis** – Satu Kuure
- 4:39 p.m. [FR-OR12](#) **Multi-Omic Profiling of Human Renal Organoids Reveals PAX8 as a Critical Regulator of Human Renal Mesenchymal-to-Epithelial Transition** – Julie Williams
- 4:48 p.m. [FR-OR13](#) **Interpreting Geometric Rules of Early Kidney Formation for Synthetic Morphogenesis** – Alex Hughes
- 4:57 p.m. [FR-OR14](#) **ZEB2 Signaling Is Essential for Ureteral Smooth Muscle Cell Differentiation and Maintenance** – Sudhir Kumar
- 5:06 p.m. [FR-OR15](#) **The Multimodal Role of TBX6 in Kidney and Urinary Tract Development and Disease** – Gregory Whittemore
- 5:15 p.m. [FR-OR16](#) **TGFβ Signaling Regulates Renal Patterning via Cadm1 During Nephrogenesis** – Sara Qubisi
- 5:24 p.m. [FR-OR17](#) **ATP-Citrate Lyase (ACLY) Is a Key Modulator of Nephron Progenitor Cell Fate Decisions In Vivo** – Giovane Tortelote
- 5:33 p.m. [FR-OR18](#) **A Single-Cell Atlas of Human Fetal Kidneys Identifies Cell States Associated with Rare and Common Human Disease** – Jonathan Levinsohn
- 5:42 p.m. [FR-OR19](#) **Identification of Genes and Regulatory Elements Affecting Human Kidney Function** – Gabriel Loeb
- 5:51 p.m. [FR-OR20](#) **Genome-Wide Association Study Across Biobanks Identifies New Susceptibility Loci for Urinary Tract Infections** – Katherine Xu

Fluid, Electrolyte, and Acid-Base Disorders: Basic Research..... Room 111

Moderators: Pablo Ortiz, Shujie Shi

- 4:30 p.m. [FR-OR21](#) **Empagliflozin Blunts Renal Mg²⁺ Wasting and Restores Distal Tubule Sodium Chloride Cotransporter (NCC) and TRPM6 Expression in Rats with Cisplatin-Induced Hypomagnesemia** – James McCormick
- 4:39 p.m. [FR-OR22](#) **Critical Role of mTORC2 in Maintaining Sodium and Potassium Balance: Implications for Aldosterone-Independent Regulation of Epithelial Sodium Channel (ENaC) in the Distal Nephron** – Bidisha Saha
- 4:48 p.m. [FR-OR23](#) **Role of KLHL3-S433 Phosphorylation in Potassium Homeostasis in Mice** – Kenichi Ishizawa
- 4:57 p.m. [FR-OR24](#) **PIEZO1 Channels Are Necessary for BK Channel-Mediated Flow-Induced K⁺ Secretion (FIKS) in the Cortical Collecting Duct (CCD)** – Rolando Carrisoza-Gaytan
- 5:06 p.m. [FR-OR25](#) **The Role of Renal Mechanotransduction in Blood Volume Sensing** – Rose Hill
- 5:15 p.m. [FR-OR26](#) **Kidney Tubular YAP Controls the Expression of Collecting Duct Aquaporins and Water Homeostasis** – Yin Xia
- 5:24 p.m. [FR-OR27](#) **Calcium-Binding Protein 39 (Cab39) Is Required for Na⁺-Cl⁻ Cotransporter (NCC) Phosphorylation in Mice** – Mohammed Feraus
- 5:33 p.m. [FR-OR28](#) **Extracellular Calcium-Sensing Receptor (CaSR) and Vasopressin Type 2 Receptor (V2R) Interaction: An Emerging Mechanism to Fine-Tune Water Permeability in Renal Cells** – Marianna Ranieri
- 5:42 p.m. [FR-OR29](#) **Inhibition of Urate Transporters and Insulin-Activated Urate Transport by SGLT2 Inhibitors** – David Mount
- 5:51 p.m. [FR-OR30](#) **ENaC Inhibition with Trimethoprim Occurs Without Changing Urinary H⁺ Excretion** – Niklas Ayase

How Sweet It Is: Basics of Diabetic Kidney Disease..... Room 121

Moderators: Michael Eadon, Alla Mitrofanova

- 4:30 p.m. [FR-OR31](#) **Decoding the Spatial Transcriptomic Landscape of Diabetic Nephropathy** – Qiwen Deng
- 4:39 p.m. [FR-OR32](#) **Spatially Localized Mesangial Cell Communication in Diabetic Kidney Disease** – Ricardo Melo ferreira
- 4:48 p.m. [FR-OR33](#) **Interferon- γ (IFN-g) Signaling in Diabetic Kidney Disease (DKD) Associated with ESKD** – Viji Nair
- 4:57 p.m. [FR-OR34](#) **Metabolomic and Transcriptomic Reveal Signature of Citrate Homeostasis in Diabetic Kidney Disease** – Soumya Maity
- 5:06 p.m. [FR-OR35](#) **Whole Blood DNA Methylation Signature, Circulating Proteins, and Risk of Progression to ESKD in Type 1 Diabetes (T1D)** – Zhuo Chen
- 5:15 p.m. [FR-OR36](#) **Single-Cell Resolution Drug Effects on RAAS Blockade in ZSF1 Rat Diabetic Kidney Disease** – Michael Balzer
- 5:24 p.m. [FR-OR37](#) **Long Noncoding RNA (lncRNA) PVT1 Induces Mitochondrial Damage and Inflammation via TRIM56 in Diabetic Kidney Disease** – Zhimei Lv
- 5:33 p.m. [FR-OR38](#) **NDUFS4 Regulates Cristae Remodeling in Diabetic Kidney Disease** – Koki Mise
- 5:42 p.m. [FR-OR39](#) **The Transcription Factor ChREBP Links Mitochondrial Lipidomes to Mitochondrial Morphology and Progression of Diabetic Kidney Disease** – Jianyin Long
- 5:51 p.m. [FR-OR40](#) **Transcriptomics of SGLT2-Positive Proximal Tubule S1 Segments in Mice: Response to Diabetes, SGLT1/2 Inhibition, or GLP1 Receptor Agonist** – Young Chul Kim

Interventions to Reduce CKD Progression..... Room 119

Moderators: Aminu Bello, Sankar Navaneethan

- 4:30 p.m. [FR-OR41](#) **Effect of Dietary Acid Reduction on Acid-Base Status of Patients with CKD but with Normal eGFR: A 5-Year Randomized Trial** – Nimrit Goraya
- 4:39 p.m. [FR-OR42](#) **Supporting Self-Management of Healthy Behaviors (SMART-HABITS) in CKD and Hypertension: A Pilot Trial** – Sarah Schrauben
- 4:48 p.m. [FR-OR43](#) **Association of Leukotriene Antagonist Use with the Incidence of ESKD** – Jessica Kendrick
- 4:57 p.m. [FR-OR44](#) **Initiation of ACE Inhibitor and ARBs in Patients with Advanced CKD** – Elaine Ku
- 5:06 p.m. [FR-OR45](#) **Sotagliflozin and Kidney and Cardiorenal Outcomes in SCORED** – David Cherney
- 5:15 p.m. [FR-OR46](#) **Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD** – Parminder Judge
- 5:24 p.m. [FR-OR47](#) **Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial** – Hiddo Heerspink
- 5:33 p.m. [FR-OR48](#) **Practice Patterns for Patient Pain Control and Outcomes Among CKD Patients: A CKDopps Analysis** – Nikhil Nair
- 5:42 p.m. [FR-OR49](#) **Implications of Follow-Up Time on the Optimal Weighting of the Acute and Chronic Slopes to Predict Treatment Effects on Clinical End Points** – Tom Greene
- 5:51 p.m. [FR-OR50](#) **Improvement in Anemia by SGLT2 Inhibitors Were More Prominent Among Those with Inflammation** – Miho Murashima

Kidney Pathology: From Classic Clinicopathologic Studies to Computational Pathology Room 109

Moderators: Laura Barisoni, Virginie Royat

- 4:30 p.m. [FR-OR51](#) **Membranous-Like Glomerulopathy with Masked Immunoglobulin G (IgG) Kappa Deposits: A Clinicopathologic Analysis of 247 Patients** – Tiffany Caza
- 4:39 p.m. [FR-OR52](#) **The Characteristics of Concurrent Anti-Glomerular Basement Membrane Nephritis and Membranous Nephropathy** – Lihong Bu
- 4:48 p.m. [FR-OR53](#) **Clinicopathologic Features of Anti-Brush Border Antibody Disease: A Series of 66 Patients** – Joel Murphy
- 4:57 p.m. [FR-OR54](#) **Clinicopathologic Characteristics, Etiologies, and Outcomes of Secondary Oxalate Nephropathy** – Samih Nasr
- 5:06 p.m. [FR-OR55](#) **Computationally Derived Tubular Features Are Prognostic of Clinical Outcomes in Glomerular Kidney Diseases** – Fan Fan
- 5:15 p.m. [FR-OR56](#) **Quantitative Characterization of Nonsclerotic Glomeruli Is Prognostic of Clinical Outcomes in Proteinuric Diseases** – Akhil Ambekar
- 5:24 p.m. [FR-OR57](#) **A Spatial Atlas of the Human Kidneys of Cell Types and Functional Tissue Units Identified in Highly Multiplexed Immunofluorescence Images** – Seth Winfree
- 5:33 p.m. [FR-OR58](#) **Multiplexed Single-Nucleus RNA and ATAC Sequencing in the Renal Biopsy Specimen** – Lubin Xu
- 5:42 p.m. [FR-OR59](#) **T Cell-Receptor (TCR)-Independent Activation of CD8 Effector T Cells by IL-15 and IFN β Drives Kidney Damage in Lupus Nephritis** – Christopher Skopnik
- 5:51 p.m. [FR-OR60](#) **Adoptive Cellular Immunotherapy for the Control of Primary Membranous Nephropathy** – Ainhua Garcia Busquets

Kidney Transplantation: Biomarkers, New and Old..... Room 115

Moderators: Mohammed Javeed Ansari, Jamil Azzi

- 4:30 p.m. [FR-OR61](#) **Correlation of HLA Matchmaker and PIRCHE Reveals T Cell Epitope Mismatches High Risk for Donor Specific Antibodies (DSA) and Antibody-Mediated Rejection (AMR)** – Clarkson Crane
- 4:39 p.m. [FR-OR62](#) **Validation of Diagnostic, Prognostic, and Predictive Performances of a Novel Urinary Exosomal mRNA Clinical Test** – Rania El Fekih
- 4:48 p.m. [FR-OR63](#) **Differential cfDNA Methylation in Kidney Allograft Rejection** – Benjamin Spector
- 4:57 p.m. [FR-OR64](#) **Urinary Endotrophin Excretion Is Associated with Graft Failure and Mortality in Kidney Transplant Recipients** – Firas Alkaff
- 5:06 p.m. [FR-OR65](#) **Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection** – Po Yee Mia Leung
- 5:15 p.m. [FR-OR66](#) **Proenkephalin A 119-159 as a Novel Biomarker for Early Detection of Delayed Graft Function After Kidney Transplantation** – Christian Nusschag
- 5:24 p.m. [FR-OR67](#) **Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study** – Chang Seong Kim
- 5:33 p.m. [FR-OR68](#) **The Molecular Microscope Diagnostics System (MMDx) Does Not Identify Molecular T Cell-Mediated Rejection (TCMR) in Cases with Borderline Changes or Isolated Intimal Arteritis in the Absence of Microvascular Inflammation** – Thomas Schachtner
- 5:42 p.m. [FR-OR69](#) **Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients with Indication Biopsy: Results of a Prospective German Single-Center Trial** – Louise Benning
- 5:51 p.m. [FR-OR70](#) **Pretransplant HbA1C as a Predictor of Kidney and Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation: A Retrospective Nationwide Study** – Jatharong Kittrakulrat

Managing the Many Facets of Home Dialysis Room 120

Moderators: Graham Abra, Nupur Gupta

- 4:30 p.m. [FR-OR71](#) **The Standardized Discontinuation Ratio: A Novel Measure for Real-Time Monitoring of Home Dialysis Discontinuation** – Eric Weinhandl
- 4:39 p.m. [FR-OR72](#) **Breaking Through Barriers with Home Hemodialysis (HHD) Group Training, Enhancing Access and Improving Patient Experience: A Single-Center Experience** – Maria Bermudez
- 4:48 p.m. [FR-OR73](#) **Hospitalisation Risk in the Integrated Home Dialysis Model: Analysis of the Canadian Organ Replacement Register** – Louis-Charles Desbiens
- 4:57 p.m. [FR-OR74](#) **Physical Activity Perceptions and Practices of People Receiving Peritoneal Dialysis: An International Cross-Sectional Survey** – Jennifer MacRae
- 5:06 p.m. [FR-OR75](#) **Decreasing the Burden: A Single-Centre Experience of Decremental Peritoneal Dialysis (PD) in Toronto, Canada** – Shabnam Hamidi
- 5:15 p.m. [FR-OR76](#) **CKD-Associated Pruritus: Prevalence and Association with Quality of Life for Peritoneal Dialysis Patients, International Results from PDOPPS** – Karthik Tennankore
- 5:24 p.m. [FR-OR77](#) **Outcomes of an Assisted Peritoneal Dialysis Program in the United States** – Wael Hussein
- 5:33 p.m. [FR-OR78](#) **QuickCheck: A Point-of-Care Method for Rapid Cell Counting in Peritoneal Dialysis-Associated Peritonitis** – Junaid Qazi
- 5:42 p.m. [FR-OR79](#) **A Cutting-Edge Multiphoton Microscopy-Based Approach to Test the Structure of the Peritoneal Membrane Reveals the Protective Effects of Glucose-Sparing Solution** – Luciano D'Apollito
- 5:51 p.m. [FR-OR80](#) **Pregnancies in Women with Kidney Failure on Home Dialysis** – Silvi Shah

Navigating a Path to Diversity and Equity in Kidney Health Room 107

Moderators: Clare Lyas, Ebele Umeukeje

- 4:30 p.m. [FR-OR81](#) **Representativeness of Randomized Control Trials in Kidney Transplantation** – Oshorenuwa Aiyegbusi
- 4:39 p.m. [FR-OR82](#) **Primary Care Clinician Perspectives on APOL1 Testing for Kidney Diseases** – Dinushika Mohottige
- 4:48 p.m. [FR-OR83](#) **Association of Unmet Social Needs with Blood Pressure Severity and Target Organ Injury: Interim Analysis of the SUPERHERO Study** – Elizabeth Onugha
- 4:57 p.m. [FR-OR84](#) **Association of Unmet Social Determinants of Health (SDOH) with Quality of Life (QoL) in Patients on Hemodialysis (HD)** – Hwei Hsun Wen
- 5:06 p.m. [FR-OR85](#) **Exploring Unconscious Bias in Peer-to-Peer Interactions in Medical Conferences: A Retrospective Analysis** – Joseph Wahba
- 5:15 p.m. [FR-OR86](#) **County-Level Structural Racism Predicts Black-White ESKD Patient Mortality Disparities** – Jonathan Daw
- 5:24 p.m. [FR-OR87](#) **Significant Variation in Kidney Disease Indicators Within Cook County, IL: Findings from Geospatial Analysis of 2022 National Laboratory Data** – Jennifer Bragg-Gresham
- 5:33 p.m. [FR-OR88](#) **Barriers and Opportunities to Increase Home Dialysis Among African American Patients** – Unini Odama
- 5:42 p.m. [FR-OR89](#) **Experiencing Discrimination Reduced the Effectiveness of the TALK Intervention on Kidney Failure Patients** – Larissa Myaskovsky
- 5:51 p.m. [FR-OR90](#) **Regional Variation in the Use of Percutaneous Kidney Biopsy in Japan** – Yasuhiro Oda

Novel Clinical Impacts on Cardiorenal Disease Room 103

Moderators: Joachim Ix, Nishigandha Pradhan

- 4:30 p.m. [FR-OR91](#) **One-Month Treatment with Dapagliflozin Triggers Renal Water Conservation and Thus Prevents Osmotic Diuresis in Patients with Chronic Heart Failure** – Adriana Marton
- 4:39 p.m. [FR-OR92](#) **Association of Polygenic Risk Scores for Blood Pressure with Incidence of Hypertension and CKD** – Soyeon Kim
- 4:48 p.m. [FR-OR93](#) **Polygenic Scores for Incident Myocardial Infarction in CKD** – Amarnath Marthi
- 4:57 p.m. [FR-OR94](#) **Kidney Function Trajectories, Risk Factors, and Outcomes in Left Ventricular Assist Device (LVAD) Recipients** – Carl Walther
- 5:06 p.m. [FR-OR95](#) **Associations Between Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease in Three Prospective CKD Patient Cohorts** – Yang Pan
- 5:15 p.m. [FR-OR96](#) **Effects of Aprocritentan for Blood Pressure Lowering and Proteinuria in Patients with CKD and Resistant Hypertension** – George Bakris
- 5:24 p.m. [FR-OR97](#) **Increased Coronary Artery Pathology in Type 2 Diabetes Without Cardiovascular Disease but with Albuminuria** – Tine Hansen
- 5:33 p.m. [Invited Lecture](#) **Tackling the Triple Threat: The American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative** – Glenn Chertow

Podocytopathy: Novel Insights and Emerging Therapeutic Targets Room 108

Moderators: Justin Chun, Haojia Wu

- 4:30 p.m. [FR-OR98](#) **Podocyte-Specific Knockout (KO) of the Natriuretic Peptide Clearance Receptor (NPRC) Ameliorates Glomerular Injury in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)** – Liming Wang
- 4:39 p.m. [FR-OR99](#) **Hemizygous Loss of Vegfa in Cap Mesenchyme Is Associated with Thrombotic Microangiopathy and Metabolic Reprogramming of the Thick Ascending Limb (TAL) Epithelium** – Dorian Kaminski
- 4:48 p.m. [FR-OR100](#) **SMPDL3b Modulates Podocyte Innate Immunity via Stimulator of Interferon Genes (STING) Activation in CKD** – Antonio Fontanella
- 4:57 p.m. [FR-OR101](#) **Podocyte-Derived Endothelin-1 and Cross-Talk with Endothelial Cells Through EdnrA Is Essential for Glomerular Injury** – Ilse Daehn
- 5:06 p.m. [FR-OR102](#) **Conditional Knockout of YAP Decreases Podocyte Adhesion and Exacerbates FSGS Progression Through $\alpha3\beta1$ Integrin** – Guangze Shao
- 5:15 p.m. [FR-OR103](#) **Paracrine Effects of Injured Podocytes on the Transcriptome of Neighboring Cells** – Yuting Zeng
- 5:24 p.m. [FR-OR104](#) **A Novel Small Therapeutic Peptide with Potential for Treating $\alpha\beta3$ -Mediated Glomerular Damage** – Yan Xu
- 5:33 p.m. [FR-OR105](#) **Prevention of Proteinuria by a Novel, Subnanomolar ApoL1 Inhibitor** – Brett Antonio
- 5:42 p.m. [FR-OR106](#) **Dynll1-PI31 Facilitated Proteasome-Mediated Degradation as a New Therapeutic Target for Interferon 2 (INF2)-Related FSGS** – Jillian Weidner
- 5:51 p.m. [FR-OR107](#) **Fasting-Mimicking Diet and Podocyte Protection** – Laura Perin

Poster Sessions

Friday, November 3 | Exhibit Hall C

Poster Topics	Board #s
NIH/NIDDK and Informational Posters – II.....	INFO01–INFO17
AI, Digital Health, Data Science – II.....	001–048
Educational Research.....	049–072
AKI: Epidemiology, Risk Factors, Prevention – I.....	073–105
AKI: Outcomes, RRT.....	106–143
AKI: Mechanisms – II.....	144–195
AKI: Mechanisms – Case Reports.....	196–234
Onconeurology: From AKI to CKD and Everything in Between.....	235–290
Bone and Mineral Metabolism: Basic.....	291–321
Diabetic Kidney Disease: Basic – I.....	322–378
Hypertension and CVD: Basic.....	379–410
Hemodialysis: Quality of Life, Symptoms, Palliative Care.....	411–462
Dialysis: Vascular Access.....	463–500
Fluid, Electrolyte, Acid-Base Disorders: Basic.....	501–543
Genetic Diseases: Cystic – Basic.....	544–584
Genetic Diseases: Tubulopathies.....	585–632
Pediatric Nephrology – II.....	633–675
Glomerular Diseases: From Inflammation to Fibrosis – II.....	676–725
Transplantation: Basic.....	726–736
Post-Transplantation and Case Reports.....	737–790
Diversity and Equity: Kidney Transplant Research.....	791–802
Health Maintenance, Nutrition, Metabolism – II.....	803–838
Women’s Health and Kidney Diseases.....	839–876
Geriatric Nephrology.....	877–914
CKD Epidemiology, Risk Factors, Prevention – II.....	915–957
CKD Interventions: Trials and Quality Improvement.....	958–983
CKD Mechanisms: From Mendel to Mars.....	984–1038
CKD Mechanisms: Progression, Fibrosis, and Beyond.....	1039–1094
COVID-19 – II.....	1095–1139
NIDDK KUH Summer Undergraduate Research Program.....	1140–1149

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.



Wi-Fi Service

Free internet access is available in the convention center throughout the meeting.





**KIDNEY
WEEK** 2023



ASN Career Fair

Meet face-to-face with top employers looking to hire!

November 2–4, 2023
9:30 a.m. – 2:30 p.m.

Located in the Exhibit Hall

ASN invites you to take part in the ASN Career Fair. Connect with employers and find your next nephrology opportunity. It's FREE to attend!

Be on the lookout for the ASN Featured Employers Guide, including open positions from top employers delivered to your inbox after Kidney Week.

Take charge of your career! Upload or update your resume on the ASN Career Center.



Get your resume in front of employers hiring nephrology professionals who search the database.



Search for jobs that are posted right from your smartphone or tablet.



Be the first to get job alerts when a new position matching your criteria is available.



Gain resume writing tips and how to prepare for an interview.

Visit careers.asn-online.org to get started!





ASN Publications: Delivering the latest in nephrology science and news

Attend the Best of ASN Journals: *JASN*, *CJASN*, and *Kidney360* session on Thursday, November 2, at 10:30 a.m. to hear from leading authors on the latest innovative clinical, translational, and basic nephrology research for advancing patient care.

**Learn more at asnjournal.org/bestof2023
or scan the QR code using your phone.**



JASN **CJASN** **Kidney360**

Manage Your ASN Kidney Week CME/CE Credits and MOC Points Now

Need ABIM/ABP MOC points?

Don't forget to submit your reflective statement after claiming CME credits.

ASN's Continuing Education (CE) program is designed to help nephrology professionals acquire and maintain the knowledge and skillset necessary to improve patient care.

Claim your Kidney Week CME/CE credits in the ASN eLearning Center before December 20, 2023, by following the instructions below:

- Visit asn-online.org/elearning
- Select the *Kidney Week 2023* module
- Select the *Questionnaire* tab; complete the *Demographic Questionnaire*
- Navigate to the *Evaluation* tab; complete the *General Evaluation* and relevant session evaluations
- Go to the *Claim Credit* tab and follow the onscreen instructions

Accreditation

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

**Learn more at asn-online.org/elearning
or scan the QR code with your mobile device.**



DAY-AT-A-GLANCE

Saturday, November 4

8:00 a.m. – 9:30 a.m.

Plenary: JASN and CJASN Recognition, Narins Award, Scribner Award,
Smith Award and Address, State-of-the-Art Lecture.....Hall A

9:30 a.m. – 2:30 p.m.

Morning Break (9:30 a.m. – 10:00 a.m.).....Exhibit Hall C
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.).....Exhibit Hall C
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.).....Exhibit Hall C

10:00 a.m. – 1:45 p.m.

Exhibitor SpotlightsExhibit Hall C
Please see pages 10-11 for the schedule and topics.

10:30 a.m. – 12:30 p.m.

Basic/Clinical Science Sessions

New Look at Antibody-Mediated Rejection, with the Murphy Endowed Lectureship Room 115
Proteinuria and Megalin: Form Meets Function.....Room 114 (Nutter Theatre)

Clinical Practice Sessions

Controversies in CKD: Honoring Jerry Yee..... Room 204
Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?..... Room 108
Emerging Technologies for Kidney Replacement Therapies..... Room 113
Onconeurology: Primer for the Nephrologist Room 201
Renal Biopsy: Clinical Correlations 2023..... Ballroom B
Technology-Enabled Kidney Disease Care..... Room 118

Translational Sessions

A Rocky Course: Bones and Stones Through the Life Span Room 119
Power of Large Biorepositories in Diabetic Kidney Disease..... Ballroom A

Special Session

ETC Home Stretch? The ESKD Treatment Choices Model,
with the Blagg Endowed Lectureship in Kidney Diseases and Public Policy..... Room 103

Oral Abstract Session

High-Impact Clinical Trials: Part 2.....Hall A

Other Event

ASN Innovation Tournament.....Exhibit Hall C

12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 12:30 p.m.

Cytokines and IgA Nephropathy: Pathogenesis and Novel TherapiesSalon A
Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in
Diabetic Kidney Disease..... Salon I
Principles of Gout Management in Patients with Kidney Diseases..... Salon L

2:00 p.m. – 4:00 p.m.

Basic/Clinical Science Sessions

Genetic Strategies to Guide Therapeutic Development..... Room 108
Innovation in Dialysis: Better Together, Including the Celeste Castillo Lee
Endowed Lectureship.....Room 114 (Nutter Theatre)
Maternal and Environmental Factors: Effect on Kidney Formation and Function..... Room 105

2:00 p.m. – 4:00 p.m.

Basic/Clinical Science Sessions

Monitoring Allograft Injury Room 120
Nephrotic Syndrome: From Structural Classification to Molecular Basis..... Ballroom A
Novel Mechanisms of Salt-Sensitive Hypertension Room 118
Novel Roles of Channels and Transporters in Kidney Diseases and CVD Room 111
Podocytopathy in Aging: Advances and Unanswered Questions Room 103
Updates on Classic and Novel Effects of FGF-23 on Mineral, Bone, and Iron Metabolism Room 119
What's Going on in the Interstitium?..... Room 107

Clinical Practice Sessions

Hiding in Plain Sight: Cases of Drugs as Kidney Toxins Room 201
Nephrology Quiz and Questionnaire 2023..... Ballroom B
Therapeutic Controversies in AKI Recovery Care..... Room 204
We Are Never over the Rainbow: Nephrology Care for the LGBTQ+ Community Room 109

Translational Sessions

Advances in the Use of Immunofluorescence and Immunohistochemistry in
Kidney Biopsy Evaluation..... Room 113
Creatinine and Metabolites in Diabetic Kidney Disease..... Room 115

4:00 p.m. – 4:30 p.m.

Afternoon Break.....Foyers of Rooms 201/204, 108, 118

4:30 p.m. – 6:00 p.m.

Clinical Practice Sessions

Liquid "Gold," Urinary Sediment Microscopy: Current Utility of an Old Tool Room 204
Noninfectious Challenges of Home Dialysis Therapies: Improving Patient Retention..... Room 113

Translational Sessions

Treatment Development in IgA Nephropathy..... Room 201
Vascular Aging: Pulsatile Hemodynamics, Arterial Stiffness, and
Cardiorenal Target Organ Damage Room 114 (Nutter Theatre)

Oral Abstract Sessions

AKI Research: Seeking New Paths to Progress Room 118
Bioengineering, Augmented Intelligence, Digital Health, and Data Science..... Room 108
COVID-19: A New Understanding and Lessons Learned Room 107
Epidemiology of CKD Progression: Who, Why, and When?..... Room 119
Fluid, Electrolyte, and Acid-Base Disorders: Clinical Research..... Room 111
Glomerular Diseases: From Multiomics to Mechanisms..... Room 103
Hemodialysis Care: Cardiovascular and Patient-Reported Outcomes..... Room 120
Kidney Transplantation: New Translational Insights..... Room 115
Nutritional and Lifestyle Interventions to Promote Health in CKD..... Room 109
Pediatric Nephrology: Clinical and Genetic Studies..... Room 105

Download the Kidney Week App
For up-to-date meeting information,
search Kidney Week in your app
store or scan the QR code here.



Saturday, November 4, 8:00 a.m. – 9:30 a.m

Plenary..... Hall A

- 8:00 a.m. **JASN and CJASN Recognition**
- 8:10 a.m. **Robert G. Narins Award** – Michael Emmett
- 8:20 a.m. **Belding H. Scribner Award** – Philip Li
- 8:30 a.m. **Homer W. Smith Award and Address “Nephrology Practice and Therapeutics Through a Genomic Lens”** – Ali Gharavi
- 9:00 a.m. **State-of-the-Art Lecture “Antibodies Against Emerging Infectious Diseases: Global Collaborations”** – Erica Ollmann Saphire

Saturday, November 4, 10:30 a.m. – 12:30 p.m.

New Look at Antibody-Mediated Rejection, Including the Barbara T. Murphy, MB BAO BCH, Endowed Lectureship Room 115
ASN gratefully acknowledges Verici Dx, Renalytix, and the American Society of Transplantation for supporting the Murphy Endowed Lectureship.

Moderators: Enver Akalin, Indira Guleria

- 10:30 a.m. **Tfh Regulation of Systemic and Graft Alloreactive B Cell Responses After Kidney Transplantation** – Peter Sage
- 11:00 a.m. **Dissecting the Mechanisms of Antibody Generation in Response to Kidney Allografts** – Anna Valujskikh
- 11:30 a.m. **Detection of Memory B Cell Responses Before Alloantibody Generation** – Oriol Bestard
- 12:00 p.m. **Novel Therapeutic Targets to Control Humoral Responses in Desensitization and ABMR: The Barbara T. Murphy, MB BAO BCH, Endowed Lectureship** – Flavio Vincenti

Proteinuria and Megalin: Form Meets Function..... Room 114 (Nutter Theatre)

Moderators: Monica Chang Panesso, Bruce Molitoris

- 10:30 a.m. **Overview of Filtered Protein Processing in the Proximal Tubule** – Andrew Hall
- 11:00 a.m. **Megalin Structure in Endosomes and at the Surface** – Andrew Beenken
- 11:30 a.m. **Megalin Traffic and Albumin Uptake in Health and Disease** – Ora Weisz
- 12:00 p.m. **Megalin in Rhabdomyolysis-Induced AKI** – Michael Hutchens

Controversies in CKD: Honoring Jerry Yee..... Room 204

ASN thanks the ASN DKD-C Steering Committee for assistance with this session.

Moderators: Michael Choi, Delphine Tuot

- 10:30 a.m. **HIF-PHIs for Treatment of Anemia: Pro** – Steven Fishbane
- 10:50 a.m. **HIF-PHIs for Treatment of Anemia: Con** – Jeffrey Berns
- 11:10 a.m. **Applying Age-Adapted Cutoffs for CKD: Pro** – Andrew Rule
- 11:30 a.m. **Applying Age-Adapted Cutoffs for CKD: Con** – Adeera Levin
- 11:50 a.m. **Measurement of Urine Albumin vs. Protein: Pro** – Josef Coresh
- 12:10 p.m. **Measurement of Urine Albumin vs. Protein: Con** – Holly Kramer

Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?..... Room 108

Moderators: Jeffrey Saland, Andrew South

- 10:30 a.m. **Vascular Effects of Dyslipidemia in Children and Adolescents** – Sarah de Ferranti
- 11:00 a.m. **Dyslipidemia in Pediatric CKD** – Smitha Vidi
- 11:30 a.m. **Adiposity, Dyslipidemia, and Cardiovascular Risk in CKD** – Ian Macumber
- 12:00 p.m. **Controversies in the Management of Dyslipidemia in Children with CKD** – Arvind Bagga

Saturday, November 4, 10:30 a.m. – 12:30 p.m.

Emerging Technologies for Kidney Replacement Therapies Room 113

Moderators: Crystal Gadegbeku, Sahir Kalim

- 10:30 a.m. **Innovations in Dialysis Access: The Future Is Now** – Monnie Wasse
- 11:00 a.m. **The Wearable or Implantable (Bio)Artificial Kidney in 2023 and Beyond** – Shuvo Roy
- 11:30 a.m. **Kidney-on-a-Chip: Simulating Kidney Functions** – Jonathan Himmelfarb
- 12:00 p.m. **Innovations in Hemodialysis Membranes: Review of the Past and Looking at the Future** – Marcos Rothstein

Onconephrology: Primer for the Nephrologist Room 201

Moderators: Sheldon Chen, Rimda Wanchoo

- 10:30 a.m. **Approaching AKI and Pseudo-AKI from Cancer Drugs** – Abhijat Kitchlu
- 11:00 a.m. **Getting to the Heart of the Matter: Hypertension and Cardiac Disease in Cancer Patients** – Prakash Gudsoorkar
- 11:30 a.m. **Managing Kidney Transplant Patients with Cancer** – Naoka Murakami
- 12:00 p.m. **Providing Compassionate Care to Patients with Cancer and Kidney Diseases** – Jennifer Scherer

Renal Biopsy: Clinical Correlations 2023Ballroom B

ASN thanks the Renal Pathology Society for assistance with this session.

Moderators: Nicole Andeen, Jean Hou

Clinical Discussant: William Whittier

- 10:30 a.m. **Renal Pathology Case Study 1** – Anatoly Urisman
- 11:00 a.m. **Renal Pathology Case Study 2** – Matthew Palmer
- 11:30 a.m. **Renal Pathology Case Study 3** – Laura Biederman
- 12:00 p.m. **Renal Pathology Case Study 4** – Carmen Avila-Casado

Technology-Enabled Kidney Disease Care Room 118

Moderators: Stanley Crittenden, Janice Lea

- 10:30 a.m. **Integrated Digital Health System Tools to Support Decision Making and Treatment Preparation in CKD** – Jamie Green
- 11:00 a.m. **Telenephrology Provider Perspectives and Clinical Outcomes** – Gaurav Jain
- 11:30 a.m. **Use of Patient-Facing Mobile Technology and Remote Patient Monitoring in Kidney Diseases** – Priya Deshpande
- 12:00 p.m. **Wearable Sensors in the Treatment of CKD and ESKD** – Jeroen Kooman

ETC Home Stretch? The ESKD Treatment Choices Model, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy Room 103

ASN gratefully acknowledges the Northwest Kidney Centers and its contributors for support of the Blagg Lectureship. ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Keith Bellovich, Edward Gould

- 10:30 a.m. **ETC Two Years In: How Did We Get Here and Where Are We Going?** – Daniel Weiner
- 11:00 a.m. **Lessons from Around the World: Building an Environment for Successful Home Dialysis** – Martin Wilkie
- 11:30 a.m. **Metrics and the Challenge of Improving Access to Kidney Transplantation: The Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy** – Sumit Mohan
- 12:00 p.m. **Navigating the New Paradigm of Kidney Care** – Suzanne Watnick

Saturday, November 4, 10:30 a.m. – 12:30 p.m.

A Rocky Course: Bones and Stones Through the Life Span Room 119

Moderators: Stuart Sprague, Katherine Wesseling-Perry

- 10:30 a.m. **Bone Health in Children with Nephrolithiasis: Is the Die Cast Early?** – Michelle Denburg
- 11:00 a.m. **Bone Health Across the Stone-Forming Life Span** – Ita Heilberg
- 11:30 a.m. **Role of Diet and Medical Therapy in the Treatment and Prevention of Bone Disease in Stone Formers** – Calyani Ganesan
- 12:00 p.m. **Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1** – David Sas

Power of Large Biorepositories in Diabetic Kidney Disease Ballroom A

Moderators: Hiddo Heerspink, Peter Rossing

- 10:30 a.m. **Pima Indian Kidney Study** – Robert Nelson
- 11:00 a.m. **TRIDENT Trial: Transformative Research In Diabetic Nephropathy** – Katalin Susztak
- 11:30 a.m. **Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories** – Afshin Parsa
- 12:00 p.m. **Nonfederal Funding Opportunities: Leveraging Large Biorepositories** – Sanjoy Dutta

High-Impact Clinical Trials: Part 2..... Hall A

Please check the Kidney Week app or the ASN website for session details.

ASN Innovation Tournament..... Exhibit Hall C

Note: Continuing education credits are not being offered for this activity.

Saturday, November 4, 12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)

Doors open at 12:30 p.m. Lunch is provided.

Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Cytokines and IgA Nephropathy: Pathogenesis and Novel TherapiesSalon A

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

- 12:45 p.m. **Introduction** – Ali Gharavi (Moderator)
- 12:55 p.m. **Roles of APRIL and BAFF in the Pathogenesis of IgA Nephropathy** – Hitoshi Suzuki
- 1:15 p.m. **Therapies Targeting BAFF and APRIL in IgA Nephropathy** – Heather Reich
- 1:35 p.m. **Questions and Answers**

Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in Diabetic Kidney DiseaseSalon I

Support is provided by an educational grant from Novo Nordisk.

- 12:45 p.m. **Introduction** – Uta Erdbruegger (Moderator)
- 12:55 p.m. **GLP1 RAs and Kidney Outcomes in Diabetes** – Katherine Tuttle
- 1:15 p.m. **GLP1 RAs as a Part of the Diabetic Kidney Disease Therapeutic Landscape** – Sylvia Rosas
- 1:35 p.m. **Questions and Answers**

Saturday, November 4, 12:45 p.m. – 1:45 p.m.

Principles of Gout Management in Patients with Kidney Diseases..... Salon L

Support is provided by an educational grant from Horizon Therapeutics USA, Inc.

- 12:45 p.m. **Introduction** – Paul Palevsky (Moderator)
- 12:55 p.m. **Pathophysiology of Hyperuricemia and Gout** – Richard Johnson
- 1:15 p.m. **Management of Complex Patients with Gout: Special Considerations in CKD and ESKD** – Angelo Gaffo
- 1:35 p.m. **Questions and Answers**

Saturday, November 4, 2:00 p.m. – 4:00 p.m.

Genetic Strategies to Guide Therapeutic Development..... Room 108

Moderators: Rasheed Gbadegesin, Matthew Wilson

- 2:00 p.m. **Potential of RNA-Based Therapy for Kidney Diseases** – Eun ji Chung
- 2:30 p.m. **Antisense Oligonucleotide Therapy in APOL1 Nephropathy** – Barry Freedman
- 3:00 p.m. **Gene Therapy in IgA Nephropathy** – Jonathan Barratt
- 3:30 p.m. **Gene Read Through Therapies in Alport Syndrome** – Ali Hariri

Innovation in Dialysis: Better Together,

Including the Celeste Castillo Lee Endowed Lectureship Room 114 (Nutter Theatre)

ASN gratefully acknowledges Travers Therapeutics and several of Celeste's family members, friends, and colleagues for support of the Celeste Castillo Lee Endowed Lectureship.

Moderators: Kerri Cavanaugh, Lisa Koester Wiedemann

- 2:00 p.m. **Co-Productive Studies of Decision Making in Kidney Replacement Therapy** – Jane Noyes
- 2:30 p.m. **Innovation in Dialysis: How Should We Measure Success?** – Laura Dember
- 3:00 p.m. **PROs and PROMs Are What Matter Most to Patients: The Celeste Castillo Lee Endowed Lectureship** – Amanda Grandinetti
- 3:30 p.m. **Patient-Centered Approaches to Symptom Control** – Kamyar Kalantar-Zadeh

Maternal and Environmental Factors: Effect on Kidney Formation and Function Room 105

Moderators: Vikas Dharnidharka, Sunder Sims-Lucas

- 2:00 p.m. **Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm** – Jennifer Charlton
- 2:30 p.m. **Maternal Insults and Susceptibility Later in Life** – Kimberly Reidy
- 3:00 p.m. **Environmental Insults and Kidney Formation and Function** – Alison Sanders
- 3:30 p.m. **Kidney Derangements Seen in Childhood due to Prenatal Insults** – Andrew South

Monitoring Allograft Injury Room 120

Moderators: Akansha Agrawal, Valeria Mas

- 2:00 p.m. **Blood Gene Transcripts** – Maarten Naesens
- 2:30 p.m. **Spatial Transcriptomics of Graft Biopsies: Can Rejection and No Rejection Coexist?** – Paolo Cravedi
- 3:00 p.m. **Urinary Biomarkers** – Rania El Fekih
- 3:30 p.m. **Intragraft Gene Transcript Detection** – Enver Akalin

Nephrotic Syndrome: From Structural Classification to Molecular Basis..... Ballroom A
ASN thanks the Renal Pathology Society for assistance with this session.

Session support is provided by an educational grant from Traverre Therapeutics, Inc.

Moderators: Shreeram Akilesh, Rachel Lennon

- 2:00 p.m. **Current Classification of FSGS and Minimal Change Disease** – Thomas Benzing
- 2:30 p.m. **Enhancing Classification of FSGS and Minimal Change Disease with Digital and Computational Pathology** – Laura Barisoni
- 3:00 p.m. **T and B Cell Dysregulation in Idiopathic Nephrotic Syndrome** – Marina Vivarelli
- 3:30 p.m. **Autoimmunity and Idiopathic Nephrotic Syndrome** – Astrid Weins

Novel Mechanisms of Salt-Sensitive Hypertension Room 118

Moderators: Cary Boyd-Shiawarski, Orson Moe

- 2:00 p.m. **ENaC-Dependent Inflammasomes in Hypertension** – Annet Kirabo
- 2:30 p.m. **Mitochondrial Dysfunction in the Pathogenesis of Salt-Sensitive Hypertension** – Allen Cowley
- 3:00 p.m. **Lysine Metabolism and Kidney Protection in Salt-Sensitive Hypertension** – Alexander Staruschenko
- 3:30 p.m. **Epigenetic Mechanisms of Salt-Sensitive Hypertension** – Toshiro Fujita

Novel Roles of Channels and Transporters in Kidney Diseases and CVD Room 111

Moderators: Lei Wang, Owen Woodward

- 2:00 p.m. **Novel Role of Histamine Receptors in the Regulation of Renal Epithelial Sodium Channel (ENaC)** – Daria Ilatovskaya
- 2:30 p.m. **Targeting the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Calcium: A New Therapeutic Approach to PKD** – Liudmila Cebotaru
- 3:00 p.m. **Mechanosensitive Piezo1 Channels Mediate Kidney Fibrosis** – Weidong Wang
- 3:30 p.m. **Inhibition of Urea Transporter Ameliorates Uremic Cardiomyopathy in CKD** – Jeff Sands

Podocytopathy in Aging: Advances and Unanswered Questions..... Room 103

Support is provided by an educational grant from Traverre Therapeutics, Inc.

Moderators: Jeffrey Miner, Clintoria Williams

- 2:00 p.m. **Podocyte Mitochondria as Therapeutic Targets in Aging** – Mariya Sweetwyne
- 2:30 p.m. **Exploring the GSK3b as a Therapeutic Target in Podocyte Senescence** – Rujun Gong
- 3:00 p.m. **HDACs and Podocyte Senescence: Novel Therapeutic Targets?** – Shuta Ishibe
- 3:30 p.m. **Considering the Role of REST in Podocyte Aging** – Guillaume Canaud

Updates on Classic and Novel Effects of FGF-23 on Mineral, Bone, and Iron Metabolism Room 119

Moderators: Mark Hanudel, Tally Naveh-Many

- 2:00 p.m. **Overview of Classical Functions of FGF-23 in CKD, Including Contribution to Pathogenesis of CKD-MBD** – Kenneth White
- 2:30 p.m. **Review of Metabolic Mechanisms for FGF-23 Elevation in CKD** – Petra Simic
- 3:00 p.m. **Effects of FGF-23 on Bone** – Aline Martin
- 3:30 p.m. **Systemic Effects of FGF-23 Peptides on Iron Metabolism** – Guillaume Courbon

What's Going on in the Interstitium? Room 107

Moderators: Satu Kuure, Norman Rosenblum

- 2:00 p.m. **Stroma Cell Types and Mechanotransduction in the Kidneys** – Thomas Carroll
- 2:30 p.m. **Neurovascular Networks in Kidney Development** – Lori O'Brien
- 3:00 p.m. **Dynamics and Heterogeneity of Kidney Lymphatics in Organogenesis** – David Long
- 3:30 p.m. **3D Kidney Interstitial Matrix** – Sarah Calve

Hiding in Plain Sight: Cases of Drugs as Kidney Toxins Room 201

Moderators: Magdalene Assimon, Stuart Goldstein

- 2:00 p.m. **Check Yourself: Immune Checkpoint Inhibitor Nephrotoxicity** – Sandra Herrmann
- 2:30 p.m. **Piperacillin/Tazobactam and Vancomycin Nephrotoxicity: Fact or Fiction** – Alexander Flannery
- 3:00 p.m. **Detecting New Nephrotoxins in an Era of Big Data** – Sandra Kane-Gill
- 3:30 p.m. **Cases of Nephrotoxin Stewardship** – Christine Stoops

Nephrology Quiz and Questionnaire 2023.....Ballroom B

Moderators: Beatrice Concepcion, Melanie Hoenig

- 2:00 p.m. **Electrolyte and Acid-Base Disturbances** – Roger Rodby
- 2:30 p.m. **Glomerular Diseases** – Dia Waguespack
- 3:00 p.m. **Transplantation** – Gaurav Gupta
- 3:30 p.m. **Kidney Replacement Therapy** – Bessie Young

Therapeutic Controversies in AKI Recovery Care Room 204

ASN thanks the ASN AKINow Recovery/Post-AKI Workgroup for assistance with this session.

Moderators: Erin Barreto, Samuel Silver

- 2:00 p.m. **Press Your Luck: Targets and Tactics to Manage BP in AKI Survivors** – Ian McCoy
- 2:30 p.m. **The Who, When, and How of RAS/SGLT2 Inhibitors in AKI Survivors** – Emily See
- 3:00 p.m. **Dialysis Distinctions: AKI vs. ESKD** – Ayse Akcan Arikan
- 3:30 p.m. **Under the Weather: Sick Day Protocols in AKI Survivors** – Jia Hwei Ng

We Are Never over the Rainbow: Nephrology Care for the LGBTQ+ Community Room 109

ASN thanks the ASN Diversity, Equity, and Inclusion Committee for assistance with this session.

Moderators: Han Eckenrode, Suzanne Martin

- 2:00 p.m. **Health Care Disparities in the LGBTQ+ Community** – Yuvaram Reddy
- 2:30 p.m. **Intersectionality: How Race and Class Interact with LGBTQ+ Identity to Impact Health Outcomes** – Dinushika Mohottige
- 3:00 p.m. **AKI and CKD Care in Transgender Patients** – David Collister
- 3:30 p.m. **Transplant Care in Transgender Patients** – Samira Farouk

Saturday, November 4, 2:00 p.m. – 4:00 p.m.

Advances in the Use of Immunofluorescence and Immunohistochemistry in Kidney Biopsy Evaluation Room 113

Moderators: Mariam Alexander, Zoltan Laszik

- 2:00 p.m. **Evaluating for Monotypic Deposits: Beyond the Usual Immunofluorescence Panel** – Dominick Santoriello
- 2:30 p.m. **Using Immunohistochemistry to Assess Complement Activation in the Kidney Biopsy** – Nicholas Medjeral-Thomas
- 3:00 p.m. **Using Artificial Intelligence in the Analysis of Kidney Immunofluorescence** – Riccardo Magistroni
- 3:30 p.m. **Using Highly Multiplexed Immunofluorescence to Further Understanding of Kidney Diseases** – Angela Sabo

Creatinine and Metabolites in Diabetic Kidney Disease Room 115

Moderators: Anna Mathew, Eugene Rhee

- 2:00 p.m. **GFR in Current Clinical Guidelines** – Pierre Delanaye
- 2:30 p.m. **GFR in Clinical Research: Revisited** – Alessandro Doria
- 3:00 p.m. **Metabolomics in Diabetic Kidney Disease** – Morgan Grams
- 3:30 p.m. **Lipidomics in Diabetic Kidney Disease** – Subramaniam Pennathur

Saturday, November 4, 4:30 p.m. – 6:00 p.m.

Liquid “Gold,” Urinary Sediment Microscopy: Current Utility of an Old Tool Room 204

Moderators: Isabelle Ayoub, Corey Cavanaugh

- 4:30 p.m. **Evidence for Urine Microscopy in Acute Tubular Injury Diagnosis and Prognosis** – Juan Carlos Velez
- 5:00 p.m. **Urine Microscopy in “AKI-itis”: GN and AIN** – Florian Buchkremer
- 5:30 p.m. **Value of Urine Microscopy in Clinical Practice: Illustration by Cases** – Jay Seltzer

Noninfectious Challenges of Home Dialysis Therapies: Improving Patient Retention ... Room 113

ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Fredric Finkelstein, Eric Wallace

- 4:30 p.m. **Knowledge Is Key: Increasing the Use of Home Dialysis Through Patient Education** – Bourne Auguste
- 4:50 p.m. **Home Hemodialysis Vascular Access Complications** – Brent Miller
- 5:10 p.m. **Prescribing Peritoneal Dialysis for Anuric Patients** – Annie-Claire Nadeau-Fredette
- 5:30 p.m. **Peritoneal Dialysis Catheter Challenges: Malfunctions, Pain, and Leaks** – Osama El Shamy

Treatment Development in IgA Nephropathy Room 201

ASN thanks the Kidney Health Initiative for assistance with this session.

Session support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Mark Lim, Patrick Nachman

- 4:30 p.m. **Perspective and Journey of a Patient Diagnosed with IgA Nephropathy** – Judy Akin
- 4:50 p.m. **Trial Design and Endpoints in IgA Nephropathy** – Heather Reich
- 5:10 p.m. **Regulatory Pathways for Drug Development, Including the Accelerated Approval Pathway** – Aliza Thompson
- 5:30 p.m. **Emerging Therapies in IgA Nephropathy** – Dana Rizk

Saturday, November 4, 4:30 p.m. – 6:00 p.m.

**Vascular Aging: Pulsatile Hemodynamics, Arterial Stiffness, and
Cardiorenal Target Organ Damage..... Room 114 (Nutter Theatre)**

Moderators: Wendy McCallum, Mahboob Rahman

4:30 p.m. **Pathophysiology of Abnormal Pulsatile Hemodynamics and Arterial Stiffness** –
Julio Chirinos

4:50 p.m. **What Is Arterial Stiffness and How Is It Measured?** – Elaine Urbina

5:10 p.m. **Arterial Stiffness and Pulsatile Hemodynamics in CKD** – Raymond Townsend

5:30 p.m. **Pathogenic Role of Arterial Stiffness in Cerebrovascular Disease and Dementia** –
Timothy Hughes



Give Your Career an Edge with Phairify

Phairify's Physician Value Exchange empowers ASN members to take charge of their career. With Phairify, US members enjoy complimentary access to personalized compensation and productivity data—valuable career management tools that can help level the negotiation playing field.

Visit Booth #605 at ASN Kidney Week
in the Exhibit Hall to learn more about how
you can access this vital resource and gain the
insights to take the next step in your career.

**Learn more at www.asn-online.org/phairify
or scan the QR code with your mobile device.**



Oral Abstract Sessions

AKI Research: Seeking New Paths to Progress.....Room 118

Moderators: Rhea Bhargava, Kianoush Kashani

- 4:30 p.m. [SA-OR01](#) **IMPROVE AKI: Sustainability of Team-Based Coaching Interventions to Improve AKI in a Cluster-Randomized Trial** – Michael Matheny
- 4:39 p.m. [SA-OR02](#) **Effects of Avasopasem Manganese on Cisplatin-Induced AKI and CKD** – Benjamin Griffin
- 4:48 p.m. [SA-OR03](#) **Effect of Terlipressin Treatment on the Incidence of Renal Replacement Therapy in Patients with Hepatorenal Syndrome and Fluid Overload: A Post Hoc Analysis of the Phase 3 CONFIRM Study** – Hani Wadei
- 4:57 p.m. [SA-OR04](#) **Niacinamide and Renal Recovery After AKI: A Randomized, Controlled Trial** – Harbir Kohli
- 5:06 p.m. [SA-OR05](#) **Impact of Using Blood Warmer During Continuous Kidney Replacement Therapy on Adverse Kidney Events and Mortality** – Aisha Abbasi
- 5:15 p.m. [SA-OR06](#) **Machine Learning-Guided Personalized Diuretic Strategy in Patients with Sepsis-Associated AKI** – Wonsuk Oh
- 5:24 p.m. [SA-OR07](#) **Association of Post-Hospitalization Vascular Biomarker Clusters with Future Heart Failure** – Audrey Shi
- 5:33 p.m. [SA-OR08](#) **The Association of Female Sex Hormones and AKI** – Ladan Golestaneh
- 5:42 p.m. [SA-OR09](#) **Dialysis Weaning Is Uncommon in the Treatment of Outpatient AKI Requiring Dialysis (AKI-D)** – Ian McCoy
- 5:51 p.m. [SA-OR10](#) **Prediction of Postdischarge Kidney Disease Progression Among Patients with Hospitalized AKI: The ASSESS-AKI Study** – Steven Menez

Bioengineering, Augmented Intelligence, Digital Health, and Data ScienceRoom 108

Moderators: Weining Lu, Pinaki Sarder

- 4:30 p.m. [SA-OR11](#) **Development of Physiologically Relevant In Vitro Model of Human Kidney Collecting Duct System Toward a Functional Kidney Replacement** – Shayan Gholizadeh
- 4:39 p.m. [SA-OR12](#) **Induced Pluripotent Stem Cell (iPSc)-Derived and Primary Podocyte-Like Cells Are Capable of Macromolecular Sieving After Culture in Scalable Scaffolds** – Thomas Gallegos
- 4:48 p.m. [SA-OR13](#) **A Novel Vascularized Human Kidney Organoid to Study Podocyte and Endothelial Health and Disease** – Joseph Maggiore
- 4:57 p.m. [SA-OR14](#) **A Mouse Glomerular Nanoscale Spatial Atlas** – Adilijiang Ali
- 5:06 p.m. [SA-OR15](#) **A Novel Glomerular Endothelium-Targeting Adeno-Associated Virus (AAV) Delivers Bacterial Proteinase to Treat Glomerulonephritis** – Shuya Liu
- 5:15 p.m. [SA-OR16](#) **Comprehensive Single-Cell Transcriptomic, Epigenomic, and Metabolomic Profiling Reveals Anatomical and Metabolic Heterogeneity in Human Kidneys** – Haikuo Li
- 5:24 p.m. [SA-OR17](#) **Improving Patient Activation via a Novel Digital Health Intervention: My Kidneys and Me, a Multicenter Randomized Controlled Trial** – Courtney Lightfoot
- 5:33 p.m. [SA-OR18](#) **The Effect of a Novel Digital Physical Activity Intervention on Health-Related Quality of Life in People with CKD: A Multicenter Randomized Controlled Trial (Kidney BEAM)** – Sharlene Greenwood
- 5:42 p.m. [SA-OR19](#) **Hemodialysis Patient App Promotes Patient Engagement and May Improve Patient Outcomes Such as Hospitalisation and Phosphate Control** – Milind Nikam
- 5:51 p.m. [SA-OR20](#) **Integrated Proteomic and Metabolomic Modules Associated with Risk of Kidney Function Decline** – Pascal Schlosser

Saturday, November 4, 4:30 p.m. – 6:00 p.m.

COVID-19: A New Understanding and Lessons Learned Room 107

Moderators: Michelle Hladunewich, Jeffrey Silberzweig

- 4:30 p.m. [SA-OR21](#) **A Soluble ACE2 Protein Improves Survival and Lowers Viral Titers in a Lethal Mouse Model of SARS-CoV-2 Infection with the Delta Variant** – Cosimo Cianfarini
- 4:39 p.m. [SA-OR22](#) **University of California Health Systems Kidney COVID Study Inpatient Cohort** – Hiba Hamdan
- 4:48 p.m. [SA-OR23](#) **Machine Learning-Based Multi-Omics Analyses Predict Disease Severity and Identify Molecular Mechanisms of COVID-Associated Kidney Injury** – Nanditha Anandakrishnan
- 4:57 p.m. [SA-OR24](#) **Longitudinal Kidney Outcomes of COVID-19-Associated AKI** – Abinet Akilu
- 5:06 p.m. [SA-OR25](#) **Monovalent and Bivalent mRNA Vaccine Effectiveness Against Severe COVID-19 Associated with Omicron Variant in Maintenance Dialysis Patients** – Nien Chen Li
- 5:15 p.m. [SA-OR26](#) **Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider** – Eric Weinhandl
- 5:24 p.m. [SA-OR27](#) **Kidney Transplant Graft Loss During 2020** – Kirsten Johansen
- 5:33 p.m. [Invited Lecture](#) **RAS Inhibition in COVID: The Trial Evidence** – Meg Jardine

Epidemiology of CKD Progression: Who, Why, and When? Room 119

Moderators: Teresa Chen, Edgar Lerma

- 4:30 p.m. [SA-OR28](#) **Abrupt Estimated Glomerular Filtration Rate Decline After Initiating Sodium-Glucose Cotransporter-2 Inhibitors Predicts Clinical Outcomes: A Systematic Review** – Yu-Shuo Tang
- 4:39 p.m. [SA-OR29](#) **Global Burden of CKD and Attributable Risk Factors in 38 Organization for Economic Cooperation and Development (OECD) Countries: Results from GBD 2019** – Hardik Desai
- 4:48 p.m. [SA-OR30](#) **The Risk of CKD in Lithium-Treated Individuals** – Gisli Gislason
- 4:57 p.m. [SA-OR31](#) **CKD Among Childbearing Age Women in the United States: NHANES 1999-2018** – Zihe Zheng
- 5:06 p.m. [SA-OR32](#) **Mortality and Transplant After Delivering on Hemodialysis: A Matched Cohort Study** – Andrea Oliverio
- 5:15 p.m. [SA-OR33](#) **Performance of Creatinine-Based GFR Estimating Equations in Young Adults** – Lesley Inker
- 5:24 p.m. [SA-OR34](#) **Discrepancy Between eGFR Cystatin C and eGFR Creatinine in Recently Hospitalized Adults** – Yumeng Wen
- 5:33 p.m. [SA-OR35](#) **Comprehensive Evaluation of CKD Heat Map** – Morgan Grams
- 5:42 p.m. [SA-OR36](#) **Hospital Health Care Costs Following Incident CKD in Japan, Sweden, and the United States** – Navdeep Tangri
- 5:51 p.m. [SA-OR37](#) **External Validation of the Klinrisk Model in US Commercial, Medicare Advantage, and Medicaid Populations** – Navdeep Tangri

Fluid, Electrolyte, and Acid-Base Disorders: Clinical Research..... Room 111

Moderators: Evan Ray, Joshua Rein

- 4:30 p.m. [SA-OR38](#) **The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General Population** – Crissy Rudolphi
- 4:39 p.m. [SA-OR39](#) **The Plasma Metabolome and Risk of Incident Kidney Stones** – Pietro Manuel Ferraro
- 4:48 p.m. [SA-OR40](#) **Dietary Potassium and Potassium Supplementation Differentially Affect Plasma Potassium in Patients with CKD** – Martin Gritter
- 4:57 p.m. [SA-OR41](#) **HARMONIZE ASIA: A Phase 3 Study to Investigate the Safety and Efficacy of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China** – June Zhao
- 5:06 p.m. [SA-OR42](#) **Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients with Chronic Syndrome of Inappropriate Antidiuresis (SIAD): A Monocentric Open-Label Proof-of-Concept Study** – Sophie Monnerat
- 5:15 p.m. [SA-OR43](#) **Safety and Efficacy of Proactive vs. Reactive Administration of DDAVP in Severe Symptomatic Hyponatremia: A Randomized Controlled Trial** – Nichanone Kanjanasuphak
- 5:24 p.m. [SA-OR44](#) **Monitoring Serum Potassium Concentration in Patients with Severe Hyperkalemia: The Role of Bloodless Artificial Intelligence (AI)-Assisted Electrocardiography** – Chien-Chou Chen
- 5:33 p.m. [SA-OR45](#) **The Δ AG/ Δ HCO₃ Ratio in Lactic Acidosis: Time for a New Baseline? – Deborah Lu**
- 5:42 p.m. [SA-OR46](#) **Arterial pCO₂ and Arterial pH from Venous Blood Gas Concurrent Measurements from 7470 Samples: An Easy Conversion of Venous to Arterial Blood by Formula** – Gabriela Araujo
- 5:51 p.m. [SA-OR47](#) **Minimizing Hypoglycemia After Intravenous Insulin Regular Therapy for Hyperkalemia** – Daniel Landry

Glomerular Diseases: From Multiomics to Mechanisms..... Room 103

Moderators: R. Tyler Miller, Ambra Pozzi

- 4:30 p.m. [SA-OR88](#) **IFN γ -Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies** – Benjamin Juliar
- 4:39 p.m. [SA-OR89](#) **Plasma Proteome Profiling for Remission Diagnosis in ANCA Vasculitis** – Ralph Kettritz
- 4:48 p.m. [SA-OR90](#) **Development of Novel Selective DDR1 Inhibitors with the Potential to Treat CKD** – Nicolas Guisot
- 4:57 p.m. [SA-OR91](#) **Spatial Metabolomics Identifies Novel Glomerular Metabolite Signatures of Normal and Diabetic Kidneys** – Leila Hejazi
- 5:06 p.m. [SA-OR92](#) **Single-Nucleus Transcriptome Profiling of the Kidney Glomerulus Identifies Cell-Specific Responses in an Autoimmune Mouse Model of Membranous Nephropathy** – Ming Huang
- 5:15 p.m. [SA-OR93](#) **Lymphangiogenesis Regulates the Differentiation and Function of Th1 Cells in Experimental Anti-Glomerular Basement Membrane (GBM) Crescentic Glomerulonephritis (cGN)** – Danni Hu
- 5:24 p.m. [SA-OR94](#) **Bub1 Is a Potential Mediator of TGF β -Induced Renal Fibrosis** – Yasuhiro Onishi
- 5:33 p.m. [SA-OR95](#) **Protective Role of RBPjk in HIV-Related CKD** – Madhulika Sharma
- 5:42 p.m. [SA-OR96](#) **Changes in Gene Expression in Fatty Acid Metabolism and De Novo Lipogenesis Are Conserved in Human CKD and Animal Models** – Lauren Elizabeth Lee
- 5:51 p.m. [SA-OR97](#) **Humanized IGHA1 Mouse Induced by Lactobacillus casei Cell Wall Extract: A Novel Galactose-Deficient Immunoglobulin A1 (IgA1) Elevated Mouse Model of IgA Nephropathy** – Run Li

Saturday, November 4, 4:30 p.m. – 6:00 p.m.

Hemodialysis Care: Cardiovascular and Patient-Reported Outcomes.....Room 120

Moderators: Rita McGill, Harini Sarathy

- 4:30 p.m. [SA-OR48](#) **Role of Midodrine in Prevention of Intradialytic Hypotension: A Randomized Cross-Over Controlled Trial** – Pajaree Krisanapan
- 4:39 p.m. [SA-OR49](#) **Association of Calcium Channel Blocker Use with Intradialytic Hypotension** – Armida Iefranc Torres
- 4:48 p.m. [SA-OR50](#) **Association Between Ultrafiltration Rates and All-Cause Death in Patients Undergoing Extended-Hours Hemodialysis Using Time-Fixed and Time-Dependent Models: The LIBERTY Cohort** – Takahiro Imaizumi
- 4:57 p.m. [SA-OR51](#) **Impact of ESRD on Stroke Risk in Atrial Fibrillation Patients** – Abdallah El Bizri
- 5:06 p.m. [SA-OR52](#) **Use and Association of Rate Control and Anti-Arhythmic Medications with Risk of Subsequent Stroke and Mortality Among Hemodialysis Patients with Atrial Fibrillation** – Benjamin Lidgard
- 5:15 p.m. [SA-OR53](#) **Hemoglobin Stability in the ASCEND-TD Trial** – Anjali Acharya
- 5:24 p.m. [SA-OR54](#) **Depletion of Plasma Aromatic Amino Acids During Hemodialysis Is Associated with Fatigue** – Subrata Debnath
- 5:33 p.m. [SA-OR55](#) **Association Between Circulating Extracellular Matrix (ECM)-Associated Molecules and Cardiovascular Outcomes in Hemodialysis Patients** – Jihyun Baek
- 5:42 p.m. [SA-OR56](#) **Plasma A β 42/A β 40 Ratio as a Biomarker for Cognitive Impairment in Patients Undergoing Hemodialysis: A Multicenter Study** – Xujiao Chen
- 5:51 p.m. [SA-OR57](#) **Using Internal Pilot Data to Create a Dynamic Recruitment Strategy: Experience from the NightLife Trial** – Katherine Hull

Kidney Transplantation: New Translational Insights.....Room 115

Moderators: Venkatesh Kumar Ariyamuthu, Ibrahim Tawhari

- 4:30 p.m. [SA-OR58](#) **Posoleucel Associated with Reduction of BK Viremia and Persistence of BK- Reactive T Cells in a Phase 2 Trial** – Anil Chandraker
- 4:39 p.m. [SA-OR59](#) **A Phase 1/2a Trial of Autologous Regulatory T Cell Therapy Together with Donor Bone Marrow Infusion in Kidney Transplantation** – Rainer Oberbauer
- 4:48 p.m. [SA-OR60](#) **Reduction of Renal Graft Fibrosis with Valganciclovir Prophylaxis for Cytomegalovirus Prevention Compared to Preemptive Therapy: Long-Term Outcomes of Randomized Controlled Trial (OVERT Study)** – Tomas Reischig
- 4:57 p.m. [SA-OR61](#) **Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database** – Nageen Anwar
- 5:06 p.m. [SA-OR62](#) **Deceased Donor Kidney Function Is Determined by Branch Chained Amino Acid Metabolism During Ex Vivo Normothermic Perfusion** – Armin Ahmadi
- 5:15 p.m. [SA-OR63](#) **The Association Between V-Set Ig Domain-Containing 4 (VSIG4) Expression and Chronicity in Transplant Kidneys** – Sang Youb Han
- 5:24 p.m. [SA-OR64](#) **Overlapping Pathologic Findings in the Kidney Allograft Biopsy: Pitfalls for the Molecular Microscope Diagnostics System (MMDx)** – Thomas Schachtner
- 5:33 p.m. [SA-OR65](#) **The Impact of Subclinical T Cell-Mediated Rejection on Subsequent Rejections and Allograft Survival in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis** – Takayuki Yamada
- 5:42 p.m. [SA-OR66](#) **Cell Subtypes and Cell-Specific Pathways Associated with Acute-to-Chronic Injury Transition in Posttransplant AKI** – Enver Akalin
- 5:51 p.m. [SA-OR67](#) **Suitability to Donate and Attitude Toward Living Kidney Donation in Older Adults: Results from the BIS Study** – Cédric Villain

Nutritional and Lifestyle Interventions to Promote Health in CKD Room 109

Moderators: Kalani Raphael, Casey Rebholz

- 4:30 p.m. [SA-OR68](#) **The Association Between Potassium Intake and Risk of CKD** – Hyo Jeong Kim
- 4:39 p.m. [SA-OR69](#) **Estimated Potassium Intake in Patients with CKD Is Associated with CKD Progression: The Fukuoka Kidney Disease Registry (FKR) Study** – Tatsuya Suenaga
- 4:48 p.m. [SA-OR70](#) **Association of Dietary Potassium and Fiber Intake with Death Risk in a Prospective Hemodialysis Cohort** – Yoko Narasaki
- 4:57 p.m. [SA-OR71](#) **Effects of a Whole-Food, Plant-Based Nutrition Education Program on Blood Pressure and Potassium Levels in CKD** – Scott Liebman
- 5:06 p.m. [SA-OR72](#) **Effect of Dietary Acid Reduction with Fruits and Vegetables vs. Oral NaHCO₃ on Parameters of Cardiovascular Health in Stage 1 CKD: A 5-Year Randomized Trial** – Nimrit Goraya
- 5:15 p.m. [SA-OR73](#) **Food Insecurity, Dietary Intake, and Mortality Among Adults with CKD** – Jenna Kiryakos
- 5:24 p.m. [SA-OR74](#) **Dietary Inflammatory Potential and Kidney Function in the Hispanic Community Health Study/Study of Latinos** – Tanya Johns
- 5:33 p.m. [SA-OR75](#) **Personalized Patient Education on Lifestyle Modification and Nutrition Management in CKD Using ChatGPT** – Prakrati Acharya
- 5:42 p.m. [SA-OR76](#) **Intradialytic Cycling Exercise Improves Arterial Stiffness in Hemodialysis Patients** – Ho-Hsiang Chang
- 5:51 p.m. [SA-OR77](#) **Oxygen Consumption Recovery Is Delayed After the Long Interdialytic Period** – Elliott Arroyo

Pediatric Nephrology: Clinical and Genetic Studies Room 105

Moderators: Namrata Jain, Patricia Weng

- 4:30 p.m. [SA-OR78](#) **Liddle Syndrome Caused by Loss-of-Function Mutations in the Ubiquitin Ligase NEDD4L** – Daniela Rotin
- 4:39 p.m. [SA-OR79](#) **Recessive Variants in MYO1C as a Potential Novel Cause of Nephrotic Syndrome** – Ronen Schneider
- 4:48 p.m. [SA-OR80](#) **Circulating Nephritin Autoantibodies Are Present in Almost 2/3 of Steroid-Naïve Pediatric Idiopathic Nephrotic Syndrome** – Astrid Weins
- 4:57 p.m. [SA-OR81](#) **Unveiling the Disproportionate Impact of Rare Kidney Diseases on Kidney Failure: A Longitudinal Analysis Using the UK National Registry of Rare Kidney Diseases (RaDaR)** – Daniel Gale
- 5:06 p.m. [SA-OR82](#) **Contemporary Infant and Neonatal Dialysis (COINED) Study: Practice Patterns and Outcomes** – Melissa Muff-Luett
- 5:15 p.m. [SA-OR83](#) **Risk Factors and Impact of Peritoneal Podoplanin in Children on Chronic Peritoneal Dialysis** – Maria Bartosova
- 5:24 p.m. [SA-OR84](#) **Preliminary Findings from the Phase 2 EPIIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular Diseases** – Kenneth Lieberman
- 5:33 p.m. [SA-OR85](#) **Assessing Baseline Cardiovascular Disease for Kids Initiating Kidney Replacement Therapy: ABCD4Kids Study** – Priyanka Khandelwal
- 5:42 p.m. [SA-OR86](#) **Molecular Pathways Associated with Early Vascular Calcification in Pediatric CKD** – Julie Bernardor
- 5:51 p.m. [SA-OR87](#) **Prospective Validation of the PERSEVERE-II AKI Prediction Model in Pediatric Septic Shock** – Natalja Stanski

Poster Sessions

Saturday, November 4 | Exhibit Hall C

Poster Topics	Board #s
NIH/NIDDK and Informational Posters – III.....	INFO01–INFO17
Bioengineering: Modeling, Diagnosis, Therapy.....	001–026
Diversity and Equity: Other Research.....	027–069
AKI: Epidemiology, Risk Factors, Prevention – II.....	070–106
AKI: Biomarkers, Imaging, Interventions.....	107–147
AKI: Mechanisms – III.....	148–194
Onconeurology: Immunological Cross-Talk.....	195–253
Pharmacology: Kinetics, Genomics, Medication-Related Problems.....	254–295
Bone and Mineral Metabolism: Stones, Calcifications, Case Reports.....	296–319
Development, Organoids, Vascularized Kidneys, Nephrons, and More.....	320–354
Pediatric Nephrology – III.....	355–395
Diabetic Kidney Disease: Basic – II.....	396–449
Diabetic Kidney Disease: Clinical – II.....	450–493
Hypertension and CVD: Clinical – II.....	494–542
Hemodialysis: Biomarkers, Translational Research.....	543–595
Hemodialysis: Case Reports, Series, QI Projects.....	596–625
Home Dialysis – II.....	626–685
Fluid, Electrolyte, Acid-Base Disorders: Clinical – II.....	686–743
Genetic Diseases: Cystic - Genetic Analysis and Extrarenal Manifestations.....	744–786
Genetic Diseases: Glomerulopathies – II.....	787–821
Glomerular Diseases: From Inflammation to Fibrosis – III.....	822–867
Glomerular Diseases: Therapeutics.....	868–926
Glomerular Diseases: Translational Studies and Biomarkers.....	927–974
Glomerular Diseases: Podocyte Biology – II.....	975–1024
Pathology and Lab Medicine – II.....	1025–1049
Transplantation: Clinical – II.....	1050–1092
CKD Epidemiology, Risk Factors, Prevention – III.....	1093–1130

**Abstract details are available in the Kidney Week app
and at www.asn-online.org/kidneyweek.**

Advance Kidney Care

Start or Renew Your ASN Membership Today



As an ASN member, you are part of a vibrant global community of more than 20,000 kidney professionals. Stay connected to this innovative, supportive, and transformative community—join or renew your membership today to receive these exclusive benefits.

Maximize the value of your ASN membership with exclusive access to:

- A community of 20,000+ nephrology colleagues.
- Member discounts to ASN educational events, programs, and products.
- Access to ASN continuing education and career advancement tools.
- Subscriptions to ASN's publications: *CJASN*, *JASN*, *Kidney360*, and *Kidney News*.
- Eligibility for research grants and travel support.
- Subscription to *In The Loop*, a daily email collating kidney-related news.
- And much more.

Visit the ASN Member Services
booth or www.asn-online.org/renew



Scientific Exposition

A vital part of the Kidney Week educational experience is found on the scientific exposition floor, Exhibit Hall C, of the Pennsylvania Convention Center. This unparalleled international venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. On the exposition hall floor, you can engage in peer-to-peer interactions with representatives and businesses that form an integral part of your day-to-day fight against kidney disease and view thousands of accepted poster abstracts.

Exhibition Schedule

Thursday

November 2

9:30 a.m. — 2:30 p.m.

Friday

November 3

9:30 a.m. — 2:30 p.m.

Saturday

November 4

9:30 a.m. — 2:30 p.m.

*Attendee Lounges are supported by
Travere Therapeutics.*

*Scientific Exposition Refreshment Breaks are supported by
Novo Nordisk.*

*The Welcome Reception is supported by
Calliditas Therapeutics.*

“We need to support a diversity of ideas. Progress comes from a good balance of disruptive research and incremental science.”

Laisel Martinez, PharmD, MS

University of Miami Miller School of Medicine

2023 KidneyCure Diversity, Equity, Inclusion, and Justice Research Scholar Grant Recipient



The trailblazing investigators funded by KidneyCure share your commitment to making a difference for the millions of patients impacted by kidney diseases. Bringing radical ideas and fresh perspectives, these determined grant recipients will advance care and find cures, such as Laisel Martinez, PharmD, MS, whose work aims to develop new anti-inflammatory therapies that will reduce vascular access failure to “improve health outcomes and the quality of life for dialysis patients.”

Your support is crucial to funding the diverse ideas that will progress our field.

Laisel Martinez, PharmD, MS, is the inaugural recipient of the KidneyCure Diversity, Equity, Inclusion, and Justice Research Scholar Grant. This grant is funded by Otsuka and Visterra, and the American Society of Nephrology.

Make a Difference

Use your phone's camera to scan the QR code. Or visit:
www.kidneycure.org/donate



Cele's Champions: Cele Fogarty Travel Support Program for Patients

On behalf of the 850,000,000 people worldwide with kidney diseases, the Cele Fogarty Travel Support Program for Patients (“Cele’s Champions”) honors people living with kidney diseases or caring for an individual with kidney diseases by supporting their voice and advocacy.

Cecilia “Cele” Agnes Fogarty was a leading executive in event management and member services for decades, advancing the work of several major organizations, including ASN, in health care, medicine, science, and other areas. She was renowned for her ability to manage the most complex meeting logistics, anticipate challenges, and meet unexpected crises—large and small—with aplomb and sometimes magic.

Despite being diagnosed with kidney disease herself, Ms. Fogarty continued to work towards “A world without kidney diseases,” including the strenuous onsite meeting management, due to the flexibility of peritoneal dialysis, and the support of her care team. Her dedication and persistence parallel the courage and diligence to live well with a chronic disease.



Patient advocates who speak out for the people worldwide with kidney diseases.

ASN is committed to including the patient voice throughout the organization and in its activities. To honor Ms. Fogarty, her commitment to mentorship, and her passion for accommodating all people regardless of the challenges they may face, ASN is pleased to announce the group of **2023 “Cele’s Champions” – patient advocates who speak out for the people worldwide with kidney diseases.**

- Joshua Albright
- Thelma Barber
- John Bayton
- Alexis Conell
- Maribel Costel
- Arnold Davis
- Valen Keefe
- Roberta Reed
- Janet Tennyson
- Dominika Woch

DAY-AT-A-GLANCE

Sunday, November 5

8:00 a.m. – 9:00 a.m.

Plenary: In Memoriam, ASN Midcareer Awards, State-of-the-Art Lecture.....	Hall A
ASN Business Meeting.....	Hall A

9:30 a.m. – 11:30 a.m.

Basic/Clinical Science Sessions

Future of T Reg Therapy in Transplantation.....	Room 105
Implementation: Breaking Barriers to Reach the Bedside.....	Room 109

Clinical Practice Sessions

Fluid Management in High-Risk Populations	Room 201
IgA Vasculitis: Updates, Progress, and Challenges.....	Room 204
Leveraging Technical Advances to Manage and Monitor Hypertension.....	Room 113
Peritoneal Dialysis: How Much Is Adequate and How Can We Improve?	Room 111

Translational Sessions

APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases	Room 107
Complement as a Target in CKD	Room 108
Potential Markers for Prediction of Kidney Outcomes	Room 103



With over 200 hours of recorded Annual Meeting presentations, Kidney Week *On-Demand* is the best way to get the most out of your Annual Meeting experience.

To get your complimentary access code, exchange this voucher at the following booth:



Booth 2005

All recorded presentations will be available in late November 2023 on the ASN eLearning Center for up to three years.
Final hours available subject to speaker permission.

Access codes are available during Exhibit Hall hours to fully paid Annual Meeting participants only.

Sunday, November 5, 8:00 a.m. – 9:00 a.m.

Plenary	Hall A
8:00 a.m.	In Memoriam
8:05 a.m.	ASN Midcareer Awards
8:15 a.m.	State-of-the-Art Lecture “Too Hot: Human Bodies and Inhuman Temperatures” – Bill McKibben

ASN Business Meeting..... Hall A

Sunday, November 5, 9:30 a.m. – 11:30 a.m.

Future of T Reg Therapy in Transplantation..... Room 105

Moderators: Anil Chandraker, Jonathan Maltzman

- 9:30 a.m. **Epigenetics, Tregs, and Transplant Survival** – Wayne Hancock
- 10:00 a.m. **Regulatory T Cell Therapy in Kidney Transplantation: Where Do We Stand?** – Joseph Leventhal
- 10:30 a.m. **Engineering Regulatory T Cells to Induce Tolerance** – Megan Levings
- 11:00 a.m. **T Reg-Mediated Regulation of Immunity Within Allografts** – Geoffrey Camirand

Implementation: Breaking Barriers to Reach the Bedside Room 109

ASN thanks the ASN AKINow Basic Science Workgroup for assistance with this session.

Moderators: Sherry Mansour, Mark Okusa

- 9:30 a.m. **Recruiting Patients as Champions in Their Care: Identifying Barriers and Promoting Self-Advocacy** – Patrick Gee
- 10:00 a.m. **Reviewing the Science: Innovations in Kidney Care** – Amy Mottl
- 10:30 a.m. **Applying the Science: Implications for Kidney Transplant Patients** – Vineeta Kumar
- 11:00 a.m. **Uniting the Science and Bedside Care: Practical Approaches for the Kidney Care Team** – Samir Parikh

Fluid Management in High-Risk Populations..... Room 201

Moderators: Michael Connor, Kathleen Liu

- 9:30 a.m. **Approach to Fluid Balance Management in Intensive Care Unit Patients with AKI** – Anitha Vijayan
- 10:00 a.m. **Fluid Balance Management in Acute Hypoxemic Respiratory Failure Caused by Acute Lung Injury** – Marlies Ostermann
- 10:30 a.m. **Does the Use of Hypertonic Saline with Diuretics in Acute Heart Failure Improve Outcomes?** – Kianoush Kashani
- 11:00 a.m. **Perioperative Fluid Management in Patients Undergoing Major Surgery** – Alexander Zarbock

IgA Vasculitis: Updates, Progress, and Challenges..... Room 204

Support is provided by an educational grant from Travers Therapeutics, Inc.

Moderators: Leal Herlitz, Mahmoud Kallash

- 9:30 a.m. **Updates in the Histologic Classification of IgA Vasculitis** – Mark Haas
- 10:00 a.m. **IgA Vasculitis: Similarities and Contrasts with IgA Nephropathy in Pathogenesis and Management** – Jonathan Barratt
- 10:30 a.m. **Secondary IgA Vasculitis: Drugs and Associated Systemic Diseases** – Camille Rasmussen
- 11:00 a.m. **IgA Vasculitis: A Different Disease in Children and Adults?** – David Selewski



EDT to EST Time Change Sunday, November 5
Don't forget to turn back your clocks one hour.

Leveraging Technical Advances to Manage and Monitor Hypertension..... Room 113

Moderators: Sandra Taler, Raymond Townsend

- 9:30 a.m. **Volume Management to Treat Hypertension in Patients with Kidney Diseases** – Jennifer Flythe
- 10:00 a.m. **BP Targets in Patients Treated with Hemodialysis** – Chi-yuan Hsu
- 10:30 a.m. **Systolic BP Time in Target Range and Major Adverse Kidney and Cardiovascular Events** – Leo Buckley
- 11:00 a.m. **Cuffless BP Devices: Ready for Prime Time?** – Jordana Cohen

Peritoneal Dialysis: How Much Is Adequate and How Can We Improve? Room 111

ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Rafia Chaudhry, Thomas Golper

- 9:30 a.m. **Peritoneal Dialysis Adequacy Beyond Kt/V_{urea}: How Much Is Enough?** – Joanne Bargman
- 10:00 a.m. **Quality of Life on Peritoneal Dialysis: What Should We Consider?** – Nicole Scholes-Robertson
- 10:30 a.m. **Fluid and Solute Transport: Can We Get More Out of the Peritoneal Membrane?** – Alena Parikova
- 11:00 a.m. **Incremental Peritoneal Dialysis: The Hallmark of Individualizing Therapy** – Jenny Shen

APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and

Mechanisms in Genetic Diseases Room 107

Moderators: Kaye Brathwaite, Patrick Brophy

- 9:30 a.m. **Molecular Mechanisms of Extrakidney Manifestations of Hereditary Nephrotic Syndrome** – Nina Mann
- 10:00 a.m. **Integrating APOL1 Testing into Clinical Practice** – Kate Bramham
- 10:30 a.m. **The Many Faces of HNF1B Mutations** – Claudia Izzi
- 11:00 a.m. **Common Variants in Mendelian Disease Genes as Risk Factors for CKD** – Tomoko Horinouchi

Complement as a Target in CKD..... Room 108

Moderators: Richard Coward, Zaipul Md Dom

- 9:30 a.m. **Complement Role Across Kidney Diseases** – Joshua Thurman
- 10:00 a.m. **Complement Activation in IgA Nephropathy** – Matthew Pickering
- 10:30 a.m. **Complement Role in Diabetic Kidney Disease: Emerging Evidence** – Melinda Coughlan
- 11:00 a.m. **Complement Inhibition: Toward Translation** – Giuseppe Remuzzi

Potential Markers for Prediction of Kidney Outcomes..... Room 103

Moderators: Josef Coresh, Sri Lekha Tummalapalli

- 9:30 a.m. **Prediction Models to Predict Incident Kidney Diseases** – Navdeep Tangri
- 10:00 a.m. **Proteomics for Predicting Outcomes in CKD** – Ruth Dubin
- 10:30 a.m. **Precision Medicine in the Prediction of Kidney Disease Progression in Diabetes** – Steven Coca
- 11:00 a.m. **Insights into the Genetic Basis of Early-Onset CKD** – Friedhelm Hildebrandt

TOP POLICY AND QUALITY VICTORIES IN 2023

- 1** Increased access to transplant care by passing the Securing the US OPTN Act, supporting the implementation of the Health Resources and Services Administration OPTN Modernization Initiative, and advancing legislation to better support living donors.
- 2** Engaged the kidney health community to support a screening recommendation for kidney diseases from the United States Preventive Services Task Force.
- 3** Advocated for consistent federal funding of innovation through KidneyX, kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases and across the federal government, kidney disease surveillance at the Centers for Disease Control and Prevention, and care of American service members at the Veterans Health Administration.
- 4** Increased awareness about kidney diseases and the challenges faced by the kidney care workforce among policymakers at local events with members of Congress and the Biden Administration.
- 5** Advanced equity within kidney health by obtaining congressional support for studying transplant disparities, advocating for regulatory changes to increase access to home dialysis and further measure and integrate social determinants of health, and raising awareness about the impact of climate change on kidney health.

Excellence in Patient Care

Championing High-Quality Kidney Care

ASN Excellence in Patient Care (EPC) focuses on clinical priorities to provide high-quality care for people with kidney diseases. Through all projects and initiatives, EPC aims to:

- Ensure all people with kidney diseases receive the best evidence-based care possible.
- Champion patient experiences, preferences, and values by actively engaging people with kidney diseases in EPC activities.
- Advance equitable access to high-quality kidney care by promoting diversity, equity, and inclusion and pursue health care justice.

Excellence in Patient Care (EPC), on behalf of the American Society of Nephrology (ASN), extends its gratitude to the leaders and volunteers of the EPC committees and workgroups. Learn more about EPC, and the Kidney Week sessions that feature its initiatives, at epc.asn-online.org or scan the QR code.





The Research, Discovery, and Innovation (RDI) department of the ASN Alliance for Kidney Health integrates three programs to stimulate, accelerate, and support biomedical research and innovations for people with kidney diseases.

- **KidneyCure** encourages and supports the kidney research and education workforce through grants and fellowships to pre-doctoral through early-career researchers.
- **Kidney Health Initiative** promotes the development of innovative treatment options for people with kidney diseases through a partnership among ASN, the US Food and Drug Administration, and more than 80 member organizations.
- **KidneyX** is a partnership between ASN and the US Department of Health and Human Services that enables the development of breakthrough treatments in kidney care.

Visit www.asn-online.org to learn more about ASN's work to increase the nephrology workforce pipeline and foster innovation in kidney care.

SAVE

the **DATE**

KIDNEY **WEEK** **20** **24**

October 23-27 | San Diego, CA



www.asn-online.org



Medical Resources and Platforms: Partnering With Experts in the Field

GSK is proud to partner with experts in the field to bring you medical education platforms to support you and your patients.



Anemia of Chronic Kidney Disease YouTube Channel



<https://www.youtube.com/@anemiaofckd/featured>

Visit the YouTube channel to view animations and expert presentations covering important topics including:

- Burden and prevalence of anemia of CKD in dialysis patients
- Latest understanding of the pathophysiology of anemia of CKD including the role of the HIF pathway
- Current management landscape and challenges within the dialysis patient population

Visit the YouTube channel
to find out more!



USMA Nephrology Portal



<https://gskusmedicalaffairs.com/nephrology/>

Navigate and explore the latest disease education on anemia of CKD and lupus nephritis through:

- Infographics
- Expert videos
- Slide presentations
- Podcasts

Visit the USMA
portal to learn more!

CKD, chronic kidney disease; HIF, hypoxia-inducible factor; USMA, United States Medical Affairs
These are non-promotional disease awareness websites and programs intended for US healthcare professionals only.
They are not Continuing Education activities.

GSK

 [gsk.com](https://www.gsk.com)

Trademarks are owned by or licensed to the GSK group of companies.
PSE-US-2051 | Date of preparation: August 2023



Ahead of Kidney Disease Together

Come visit us at
BOOTH #1630



 [gsk.com](https://www.gsk.com)

Trademarks are owned by or licensed to the GSK group of companies.
PSE-US-2051 | Date of preparation: August 2023